


In the format provided by the authors and unedited.

Butler enables rapid cloud-based analysis of thousands of human genomes

Sergei Yakneen^{1,2,6}✉, Sebastian M. Waszak¹, PCAWG Technical Working Group³, Michael Gertz², Jan O. Korbel^{1,4}✉ and PCAWG Consortium⁵


¹European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany. ²Institute of Computer Science, Heidelberg University, Heidelberg, Germany. ³A list of members and affiliations appears at the end of the paper. ⁴EMBL, European Bioinformatics Institute (EMBL-EBI), Hinxton, UK. ⁵A list of members and affiliations appears in Supplementary Note 2. ⁶Present address: Sophia Genetics SA, Saint Sulpice, Switzerland.
✉e-mail: llevar@gmail.com; jan.korbel@embl.de



Supplementary Figure 1

Freebayes workflow


Freebayes workflow can be used for small variant discovery and genotyping and splits into tasks by chromosome, where each task can run in parallel (not all tasks are visible in figure to save space). Workflow is started and ended by standard start_analysis_run and end_analysis_run that keep track of Analysis state. validate_sample makes sure that access to the data is available.



Supplementary Figure 2

Freebayes task durations


Boxplot of freebayes task durations during the SNV genotyping stage across 5668 samples. Durations are highly correlated with chromosome length (Pearson's $r=0.92$). n=5668 biologically independent samples Boxplot center line corresponds to the median, lower and upper hinges to the 25%th and 75%th percentiles, and whiskers to ± 1.5 Interquartile range from the hinges. The experiment was performed once.



Supplementary Figure 3

Delly workflow durations


(a) Distribution of Delly workflow durations for genotyping of 244,889 germline deletions across 5668 PCAWG samples. (b) Distribution of Delly workflow durations for genotyping of 217,433 germline duplications across 5668 PCAWG samples. n=5668 biologically independent samples. The experiment was performed once.



Supplementary Figure 4

Analysis Tracker UML diagram

The Analysis Tracker consists of four entities that are necessary for keeping track of the state of scientific analyses run in Butler. The Workflow object keeps a registry of known workflows and their attributes. The Analysis object keeps track of analyses that are being performed. An Analysis Run represents an instance of running a particular workflow under a particular analysis on a particular sample. Configuration objects keep track of the parameters supplied to the workflow invocation.



Supplementary Figure 5

Analysis Run state transitions

Each Analysis Run keeps track of its state and has a set of rules governing allowable state transitions. A Run is created in the Ready state from which it may be scheduled for execution. Once the corresponding workflow task is picked up for execution it is transitioned to In-Progress. Upon successful completion it is marked Completed. At any point a failure may put this run in an Error state from which it

can recover only to the Ready state to initiate a re-execution of the corresponding workflow.

Analysis Run

config

Workflow Execution Context

Analysis

config

Effective Configuration


Workflow

config

Supplementary Figure 6

Hierarchical tri-level configuration


Configuration can be applied at three levels of granularity within Butler - Workflow, Analysis, and Analysis Run. Each higher level configuration may override and augment the configurations supplied at lower levels. At runtime all three levels of configuration are resolved into an “effective configuration”, which is then applied for execution.



Supplementary Figure 7

Butler compute cluster performance metrics during germline deletion genotyping for PCAWG

(a) Overall load per VM that is part of the Butler cluster - shows no load prior to analysis kick-off, then steady load throughout the analysis, and drop-off in load at the end when VMs start running out of work. (b) CPU profile shows highly variable CPU utilization that is typical of Delly executions. (c) Memory profile is stable and similar between all VMs that are running the analysis. Similar measurements have been observed over the other 5 analyses performed with Butler during PCAWG, although the exact pattern of CPU and Memory utilization is dependent on the algorithms that comprise the workflow being executed.



Supplementary Figure 8

SQL Database state monitoring dashboard

SQL Database health can be ascertained from logs harvested on the database server. (a) 75th, 99th, and 99.5th percentile of query response times. (b) Count queries by type. (c) Database READ and WRITE counts. (d) Data throughput in and out. These measurements were collected over a single 2-hour run of the software and serve as an example of visualization capabilities, not an indication of typical database performance.

Supplementary Tables

	PCAWG Tech	Butler	Toil	Nextflow	GenomeVIP
Language	Java	Python	Python	Groovy	PHP
Cloud platforms with full support*	3	4	1	1	1
Cloud platforms with partial support**	0	8	1	0	0
HPC support	No	No	Yes	Yes	Yes
Software Configuration Management	Yes	Yes	No	No	No
Networking and security	No	Yes	No	No	No
Health Metrics	No	Yes	No	No	No
Log Harvesting	No	Yes	No	No	No
Anomaly Detection	No	Yes	No	No	No
Multi-channel Alerting	No	Yes	No	No	No
Self-healing	No	Yes	No	No	No
Docker support	Yes	Yes	Yes	Yes	No
CWL support	Yes	Yes	Yes	No	No
Code sharing integration	Yes	Yes	No	Yes	No
Workflow modules	No	Yes	No	Yes	No
DAG Rendering	Yes	Yes	Yes	Yes	Yes
Distributed Cluster support (Spark, Mesos)	No	Yes	Yes	Yes	No

Supplementary Table 1 - Comparison of cloud-enabled scientific workflow frameworks. * full support is defined here to mean that all or most features of the framework are available on that cloud, including automated configuration, networking, security, storage, metrics, monitoring, and anomaly detection. **

partial support is defined to mean that only a partial implementation exists for a cloud, with fewer features, manual setup, or limited testing.

Machine	CPU	RAM(GB)	Disk(GB)	Roles	Count
salt-master	4	6	50 ephemeral 1000 block for metrics storage	salt-master consul-bootstrap monitoring-server	1
tracker	4	4	40 ephemeral 1000 block for elasticsearch	tracker consul-server elasticsearch	1
job-queue	4	4	40 ephemeral	job-queue consul-client	1
db-server	8	16	80 ephemeral 1000 block for db	db-server consul-client	1
worker	8	32	100 ephemeral	worker germline consul-client	175

Supplementary Table 2 - Butler deployment on EMBL-EBI Embassy Cloud

Core PCAWG	
BWA	0.16
Broad	0.14
Sanger	0.07
OxoG	0.14
Butler	
SNV Discovery	0.27
SNV Genotyping	0.90
SV Duplications	0.39
SV Deletions	0.28

Supplementary Table 3 - Optimal rates for PCAWG and Butler pipelines.

Supplementary Note 1

Below is a detailed description of the various sub-systems of Butler.

Cluster Lifecycle Management

This sub-system deals with the task of creating and tearing down clusters on various clouds, including defining VMs, storage devices, network topology, and network security rules. To fulfill these requirements in a cloud agnostic manner Butler utilizes an open-source framework called Terraform, developed by Hashicorp. Terraform uses a proprietary human- and machine-readable file format for specifying cluster configurations that is called HashiCorp Configuration Language (HCL). Using this language the end user can define a number of constructs for cluster management. The key task of Terraform is to perform Create, Read, Update, and Delete on cluster resources. Running Terraform causes the tool to inspect the current state and compare it to the target state, issuing any necessary commands to update current state to the target. Butler comes with a set of Terraform configuration files that define templates for all of the VMs that constitute a functional Butler cluster, as well as configurations for network security. A typical Butler cluster consists of Control VMs and Worker VMs and templates for both are available. The users are expected to adapt the templates as needed for their use case, providing their own credentials, cluster size, and other configurations.

Cluster Configuration Management

This sub-system deals with configuration and software installation of all VMs in the cluster. VMs typically will have hundreds of programs installed and configured on them, oftentimes with intricate interdependencies and inter-machine communication requirements. The Saltstack open-source Configuration Management system integrated in Butler allows managing these dependencies and installation details independently of the Operating System (OS) chosen for the Virtual Machines for deployments involving hundreds of servers (**Figure 1**). The Configuration Management System is controlled by a Master node that acts as the authority on the state of a cluster of Minion nodes. The Master has a set of configuration definitions defined and accessible through a git repository. Each Minion can have a number of roles assigned to it, and the Master maintains mappings between roles and configuration definitions. Once the Master has determined what roles a Minion has it can issue the necessary commands to apply relevant configurations to the Minion. Butler ships with configuration definitions required to run Butler itself as well as those needed to execute the bundled workflows (for example, sequence alignment with BWA, germline variant calling with freebayes and Delly, and somatic variant calling with Sanger Institute's CGP tools). Additional configurations can be defined by the user as necessary.

Workflow System

The Workflow sub-system is responsible for allowing users to define and run scientific workflows on the cloud. Butler integrates the open-source distributed workflow system called Airflow, originally developed by Airbnb (www.airbnb.com), for this purpose. The key component at the heart of Airflow is the Airflow Scheduler (**Figure 1**). The airflow-scheduler is a service that runs perpetually on a VM and examines the state of all running workflows. All workflow tasks that meet the preconditions for being runnable are immediately "scheduled" for execution. In the context of Airflow scheduling means depositing the task into a queue (running on a separate Queue Server VM) from which a Worker VM (**Figure 1**) can eventually pick it up. The Worker VMs run an airflow-worker service that periodically polls the task queue for available tasks, and when the task is runnable by a particular Worker, that Worker consumes the task message from the queue and assumes execution. In order to keep track of the status of Workers and workflow execution each Worker periodically sends heartbeat messages to the Scheduler to communicate its state. The state is persisted by the Scheduler to a PostgreSQL database, which runs on a DB Server VM (**Figure 1**).

The user can communicate with and commandeer Airflow via the Airflow CLI, as well as a Web UI. The Web UI is provided via the airflow-flower, and airflow-webserver services, which can run on the same VM as the Scheduler or on a separate VM, depending on system load. Conceptually, an Airflow workflow is a Directed Acyclic Graph whose vertices represent tasks and edges indicate task sequence. In its implementation, an Airflow workflow is a Python program that can use any Python language construct or library. This allows the users to create workflows of arbitrary complexity and functionality.

An Analysis Tracker module is built into Butler in order to allow the user to define analyses, specify what workflows are part of these analyses, and track the status and execution of Analysis Runs - instances of running a particular workflow on a particular data sample within the context of an Analysis (**Supplementary Figure 4**).

When an Analysis Run is first created it is given a Ready status (**Supplementary Figure 5**), indicating that it is ready to be scheduled for execution. Once the Scheduler has scheduled the Run for execution it is given a Scheduled status. When workflow execution starts the Run is marked In-Progress. Once the Run is successfully completed it enters a Completed status. If, at any point, the Run encounters an error condition it cannot recover from, the Run Status is set to Error. When the error condition is addressed the Run status should be set to Ready so that it can start from the beginning.

In order to fulfill the workflow configuration and parametrisation requirements Butler implements a tri-level configuration mechanism (**Supplementary Figure 6**), allowing the user to specify configurations at Workflow, Analysis, and Analysis Run levels. At runtime all three configuration levels are merged into one "effective" configuration that applies within the execution context. Because it is important for configurations to be both human-readable and machine-readable Butler uses the JSON format to encode

configuration information. PostgreSQL, in turn, has native support for storage and deep querying of JSON values, thus making it an ideal choice for configuration persistence.

Operational Management

This sub-system provides tools for ensuring continuous successful operation of the cluster, as well as for troubleshooting error conditions. In general, the Operational Management tools fall into two categories, those that collect observations about the state of each component in the system at runtime, and those that aggregate this data and present it to the user in the form of queryable databases and management reports. We delineate two major sources of data that are indicative of system state - System Metrics, and Server Logs. While metrics provide more of a coarse-grained view of the overall health of a particular Virtual Machine, server logs can give much more of a fine-grained view of the underlying system at an application level, and down to individual lines of code that are running at any given time. Butler has dedicated components for the collection and management of these data sets

Each VM runs a metric collection daemon called Telegraf, which is an open-source package that is able to make periodic measurements of a large number of system metrics and ship them off to a centralized Monitoring Server. The definition for which metrics are collected is specified in a special configuration file. Because we are interested in observing not only the metrics as they are measured in the present, but also the dynamics of how metric values change over time, we need a mechanism for persisting this information. For this purpose the Monitoring Server component of Butler contains an instance of a database product called InfluxDB, which is an Open Source database system that is optimized for recording time series data.

The metrics collection system is collecting 50 different metrics per host on average, sampled at intervals of 10 seconds. Given a cluster of 200 Virtual Machines the monitoring system collects and stores 86,400,000 data points in a 24 hour time period. This volume of data is quite difficult for the user to comprehend and make use of, and Butler provides visualization tools to enable the display of aggregate statistics based on the monitoring data using a Graphical User Interface (**Supplementary Figure 7**). The main goal of the visualizations is to give the user an overview of the trends observed within the compute cluster with respect to a set of representative performance metrics, and to alert the user to any conditions that threaten the health of Virtual Machines and the scientific analyses they run.

Because of the potentially extremely high value of the information contained in server logs, we deploy a system of log harvesting and centralized storage that enables the Virtual Machines that are part of Butler to parse the logs that are being generated locally for interesting events and send those events to a centralized search index which is amenable to efficient querying and visualization. These open-source tools are known as the ELK stack (Elasticsearch, Logstash, Kibana).

Each Virtual Machine in the cluster runs a log shipper - Filebeat. It is responsible for finding, harvesting, and locally aggregating logs. Logstash runs on a separate centralized server and is responsible for parsing the logs forwarded from Filebeat and sending the parsed information on to the Elasticsearch index. Elasticsearch is a general-purpose scalable text indexing and search engine that supports clustering and sharing of data. Just as it is difficult to grasp and analyze performance metrics due to the number of data-points generated, it is as difficult to grasp log messages from a large cluster. We utilize a similar set of visualization tools to the ones we use for metrics, to solve this problem for server logs within Butler. The Kibana dashboarding framework allows us to create graphical dashboards that visualize log events of interest, as well as providing a web-based query interface to the Elasticsearch log messages index (**Supplementary Figure 8**).

The Monitoring Server runs an anomaly detection and alerting library called Capacitor, which defines a series of rules that specify the normal operating conditions for the cluster, such as all hosts regularly responding to ping, CPU below 80%, disk utilization below 85%, workflow tasks and other Butler services sending heartbeats every minute. Coupled with the application metrics gatherer *statsd*, the system builds an empirical distribution of the duration of various workflow tasks and knows when tasks take longer than they historically have. The anomaly detection software monitors the time series database that records all metrics and periodically evaluates the rule-set against it. When the system detects a breach of one or more rules it can take a remedial action, such as sending a warning email, a message to a Slack topic, a Telegram, or schedule the restart of a particular service, workflow or the reprovisioning of a particular VM (**Figure 1 b**). These abilities allow Butler users to be always up to date about the health of the system and allow Butler clusters to self-heal when they encounter problematic scenarios.

This approach is markedly different, and offers dramatic improvements, over error handling routines implemented in other workflow frameworks. Nextflow, for instance, provides a workflow *onError* event handler and an *errorStrategy* (<https://www.nextflow.io/blog/2016/error-recovery-and-automatic-resources-management.html>); these allow for simple retry logic to be set up including the ability to request more resources (such as memory) during the retries, and possibly notify users via email – but to trigger this routine requires that a workflow can signal the error, which in practice will often not be the case. Toil, similarly, allows for job retries upon failure (<http://toil.readthedocs.io/en/releases-3.6.x/running/running.html#error-handling-and-resuming-pipelines>), again requiring that workflows are able to report crashes. These routines, therefore, are predicated on the workflows actually failing and being able to report that. In practice, workflow failure may not happen right away, may not happen at all, or may not be successfully reported, for example when systemic IT infrastructure issues are the root cause of failure – which in practice leaves significant gaps and is the cause of some of the hardest to detect, and costly project issues. Additionally, before the underlying issue is resolved, no amount of retrying will cause the workflow to succeed, ensuring that the workflow retry logic on its own has limited utility in practice.

For example, consider a scenario where the job scheduler component crashes or stops responding. This does not cause any jobs to fail because they are handled by the worker nodes. Instead, new workflows simply fail to get scheduled, causing the system to slowly run out of work and become idle. In a large deployment with hundreds of VMs this condition quickly becomes costly, yet may go undetected because no workflows are failing. Butler deals with these situations easily, since it collects heartbeats from all essential services. As soon as the heartbeat is missing for a pre-determined period of time an alert is raised. Butler's self-healing agent will communicate with Butler's Configuration Server using its HTTP API and will instruct the Configuration Server to restart the Workflow Scheduler (**Figure 1 b**). If it is not able to bring the scheduler back online automatically it will alert users via email and Slack notifications.

It is important to understand that even though Butler provides the anomaly-detection and self-healing framework along with some preconfigured rules and actions, the types of rules and actions that it makes sense to deploy at a given time is highly dependent on the context of the analysis being performed and the IT infrastructure that the system is deployed on. Thus, users should expect to spend effort working within this framework to properly set up and tune the rules that will best serve their needs. For example, if users set up a rule of the form "Automatically reschedule workflow tasks that have taken above 3 standard deviations of the mean runtime and have not yet completed" and train this rule on a workflow that analyses small bacterial genomes, but then decide to deploy it on an organism with a much larger genome, this rule may trigger unnecessarily given marked differences in expected and acceptable runtimes. While high levels of automation can be extremely powerful and save time and costs when used in the right context, they may also wreak havoc when ill-configured.

There are in general three types of situations that the anomaly detection and self-healing components can go after:

The most high-level scenario involves detecting and resolving when an entire VM becomes stuck or otherwise unresponsive. Detection is accomplished via an *uptime* metric, which is collected for all hosts and measures how long each host has been up. If this metric is not updated for a long time the VM can be considered "dead". This is fairly easy to deal with when a VM is a worker node; a new node can simply be launched using Butler's existing provisioning functionality. It is more difficult to replace one of the management nodes in an automated fashion due to the need to rescue and migrate existing services like databases and queues. Thus, it is recommended to run these services with standby backups if high availability is desired and manually replace the nodes that go out of commission.

At times, one of the individual services that Butler relies upon for its operation will crash. The greatest majority of these can be solved by a service restart. Butler collects a heartbeat from all such services and when the heartbeat is not detected will attempt to restart the offending service via the Configuration Server (**Figure 1 b**). As Butler collects detailed statistics about each service it can potentially act on some other conditions that may affect a service (such as running out of disk space) in an automated fashion. There

are scenarios, however, such as network outages, which are impossible to fix automatically; if Butler is not able to bring the service back online after several tries it will notify a human via email and Slack notifications to ensure the issue will be resolved through human intervention, in a timely manner.

The most advanced and fine-grained application of anomaly-detection is instrumenting individual workflows with metrics using the *statsd* library in order to collect timings, CPU, memory, and disk footprint. This allows the finest degree of automated control over workflow execution letting the system operator to detect workflows that are not crashing, but are not likely to ever finish because of a bug in the software or a data issue. Setting appropriate detection thresholds for these types of events requires detailed understanding of the resource requirements and usage patterns of the underlying algorithms that are being implemented by the workflow. Usage of these features is highly recommended for large-scale, long-running projects (*e.g.* studies at the scale of PCAWG or PPCG) or for ongoing production operations with a high degree of tuning.

Although the anomaly-detection and self-healing capabilities of Butler are extremely powerful, they also have some remaining limitations. Since these components themselves are not immune to failure, adverse events that impact their ability to function will inevitably prevent the system from being able to adequately detect and respond to other failures. This includes failures of individual metrics collection agents, the time-series database, the rules engine, and the configuration server, as well as system-wide events like network outages that prevent VMs from being able to communicate with each other. In this regard the time series database and the rules engine stand out as single points of failure for the entire self-healing functionality while the failure of other components will only have a limited effect. These key components, however, can be deployed in cluster mode with standby backups to mitigate the risk of such events. One additional source of issues that is difficult for the self-healing functionality to address is the class of errors caused by data issues. Such issues are virtually impossible to deal with generically, and require a degree of expert understanding of the underlying data sets and data formats that we would advise against implementing at this level of a workflow system. Instead, we would recommend implementing the data quality assurance steps as a separate workflow that should run over the samples before they undergo further analysis.

The anomaly detection and self-healing capabilities of Butler implement a host-, service-, and workflow-level quality assurance framework that dramatically increases system robustness when operating at large scale. It should be used with care, however, to not over-automate, inadvertently introducing false-positive signals, in order for the users to reap the most benefit from this powerful functionality.

The Butler framework consists of many different services that reside on a number of different servers and need to be able to communicate with each other. To accomplish this in a flexible manner we needed to establish a Service Registry so that IP addresses of servers that host particular services can be looked up by service name. To accomplish this, Butler uses an open-source service discovery framework called Consul. Consul provides a cross-data-center distributed Service Name Registry that is available via

HTTP and DNS protocols. In addition to registry capabilities Consul provides basic health checks for the underlying services, testing whether the IP and port the service is supposed to be listening on are actually reachable.

Supplementary Note 2

PCAWG Membership List

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium

Writing Committee

Writing Committee Leads Peter J. Campbell^{1,2,747*}, Gad Getz^{3,4,5,6,747*}, Joshua M. Stuart^{9,747*}, Jennifer L. Jennings^{10,11}, Lincoln D. Stein^{12,13,747*} & Jan O. Korbel^{7,8,747*},

Sample collection Marc D. Perry^{14,15}, Hardeep K. Nahal-Bose¹⁵ & B. F. Francis Ouellette^{16,17}

Histopathology harmonization Constance H. Li^{12,18}, Esther Rheinbay^{3,6,19}, G. Petur Nielsen¹⁹, Dennis C. Sgroi¹⁹, Chin-Lee Wu¹⁹, William C. Faquin¹⁹, Vikram Deshpande¹⁹, Paul C. Boutros^{12,18,20,21}, Alexander J. Lazar²², Katherine A. Hoadley^{23,24}, Lincoln D. Stein^{12,13} & David N. Louis¹⁹

Uniform processing, somatic and germline variant calling L. Jonathan Dursi^{12,25}, Christina K. Yung¹⁵, Matthew H. Bailey^{26,27}, Gordon Saksena³, Keiran M. Raine¹, Ivo Buchhalter^{28,29,30}, Kortine Kleinheinz^{28,30}, Matthias Schlesner^{28,31}, Junjun Zhang¹⁵, Wenyi Wang³², David A. Wheeler^{33,34}, Li Ding^{26,27,35} & Jared T. Simpson^{12,36}

Methods section ‘Core alignment and variant calling by cloud computing’ Christina K. Yung¹⁵, Brian D. O’Connor^{15,37}, Sergei Yakneen⁸, Junjun Zhang¹⁵, Kyle Ellrott³⁸, Kortine Kleinheinz^{28,30}, Naoki Miyoshi³⁹, Keiran M. Raine¹, Adam P. Butler¹, Romina Royo⁴⁰, Gordon Saksena³, Matthias Schlesner^{28,31}, Solomon I. Shorser¹² & Miguel Vazquez^{40,41}

Methods section ‘Integration, phasing and validation of germline variant call sets’ Tobias Rausch⁸, Grace Tiao³, Sebastian M. Waszak⁸, Bernardo Rodriguez-Martin^{42,43,44}, Suyash Shringarpure⁴⁵, Dai-Ying Wu⁴⁶, Sergei Yakneen⁸, German M. Demidov^{47,48,49}, Olivier Delaneau^{50,51,52}, Shuto Hayashi³⁹, Seiya Imoto³⁹, Nina Habermann⁸, Ayellet V. Segre^{3,53}, Erik Garrison¹, Andy Cafferkey⁷, Eva G. Alvarez^{42,43,44}, José María Heredia-Genestar⁵⁴, Francesc Muyas^{47,48,49}, Oliver Drechsler^{47,49}, Alicia L. Bruzos^{42,43,44}, Javier Temes^{42,43}, Jorge Zamora^{1,42,43,44}, L. Jonathan Dursi^{12,25}, Adrian Baez-Ortega⁵⁵, Hyung-Lae Kim⁵⁶, Matthew H. Bailey^{26,27}, R. Jay Mashl^{27,57}, Kai Ye^{58,59}, Ivo Buchhalter^{28,29,30}, Anthony DiBiase⁶⁰, Kuan-lin Huang^{27,61}, Ivica Letunic⁶², Michael D. McLellan^{26,27,35}, Steven J. Newhouse⁷, Matthias Schlesner^{28,31}, Tal Shmaya⁴⁶, Sushant Kumar^{63,64}, David C. Wedge^{1,65,66}, Mark H. Wright⁴⁵, Venkata D. Yellapantula^{67,68}, Mark Gerstein^{63,64,69}, Ekta Khurana^{70,71,72,73}, Tomas Marques-Bonet^{74,75,76,77}, Arcadi Navarro^{74,75,76}, Carlos D. Bustamante^{45,78}, Jared T. Simpson^{12,36}, Li Ding^{26,27,35}, Reiner Siebert^{79,80}, Hidewaki Nakagawa⁸¹, Douglas F. Easton^{82,83}, Stephan Ossowski^{47,48,49}, Jose M. C. Tubio^{42,43,44}, Gad Getz^{3,4,5,6}, Francisco M. De La Vega^{45,46,78}, Xavier Estivill^{47,84} & Jan O. Korbel^{7,8}

Methods section ‘Validation, benchmarking and merging of somatic variant calls’ L. Jonathan Dursi^{12,25}, David A. Wheeler^{33,34}, Christina K. Yung¹⁵, Li Ding^{26,27,35} & Jared T. Simpson^{12,36}

Data and code availability Junjun Zhang¹⁵, Christina K. Yung¹⁵, Sergei Yakneen⁸, Denis Yuen¹², George L. Mihaiescu¹⁵, Larsson Omberg⁸⁵ & Vincent Ferretti^{15,86}

Pan-cancer burden of somatic mutations Junjun Zhang¹⁵ & Peter J. Campbell^{1,2}

Panorama of driver mutations in human cancer Radhakrishnan Sabarinathan^{87,88,89}, Oriol Pich^{87,89} & Abel Gonzalez-Perez^{87,89}

PCAWG tumours with no apparent driver mutations Esther Rheinbay^{3,6,19}, Amaro Taylor-Weiner⁹⁰, Radhakrishnan Sabarinathan^{87,88,89}, Peter J. Campbell^{1,2} & Gad Getz^{3,4,5,6}

Patterns and oncogenicity of kataegis and chromoplexy Matthew W. Fittall⁹¹, Jonas Demeulemeester^{91,92}, Maxime Tarabichi^{1,91}, Nicola D. Roberts¹, Peter J. Campbell^{1,2}, Jan O. Korbel^{7,8} & Peter Van Loo^{91,92}

Patterns and oncogenicity of chromothripsis Maxime Tarabichi^{1,91}, Jonas Demeulemeester^{91,92}, Matthew W. Fittall⁹¹, Isidro Cortés-Ciriano^{93,94,95}, Lara Urban^{7,8}, Peter Park^{94,95}, Peter J. Campbell^{1,2}, Jan O. Korbel^{7,8} & Peter Van Loo^{91,92}

Timing-clustered mutational processes during tumour evolution Jonas Demeulemeester^{91,92}, Maxime Tarabichi^{1,91}, Matthew W. Fittall⁹¹, Jan O. Korbel^{7,8}, Peter J. Campbell^{1,2} & Peter Van Loo^{91,92}

Germline genetic determinants of the somatic mutation landscape Sebastian M. Waszak⁸, Bin Zhu⁹⁶, Bernardo Rodriguez-Martin^{42,43,44}, Esa Pitkänen⁸, Tobias Rausch⁸, Yilong Li¹, Natalie Saini⁹⁷, Leszek J. Klimczak⁹⁸, Joachim Weischenfeldt^{8,99,100}, Nikos Sidiropoulos¹⁰⁰, Ludmil B. Alexandrov^{1,101}, Francesc Muyas^{47,48,49}, Raquel Rabionet^{47,49,102}, Georgia Escaramis^{47,103,104}, Adrian Baez-Ortega⁵⁵, Mattia Bosio^{40,47,49}, Aliaksei Z. Holik⁴⁷, Hana Susak^{47,49}, Eva G. Alvarez^{42,43,44}, Alicia L. Bruzos^{42,43,44}, Javier Temes^{42,43}, Aparna Prasad⁴⁹, Nina Habermann⁸, Serap Erkek⁸, Lara Urban^{7,8}, Claudia Calabrese^{7,8}, Benjamin Raeder⁸, Eoghan Harrington¹⁰⁵, Simon Mayes¹⁰⁶, Daniel Turner¹⁰⁶, Sissel Juul¹⁰⁵, Steven A. Roberts¹⁰⁷, Lei Song⁹⁶, Roelof Koster¹⁰⁸, Lisa Mirabello⁹⁶, Xing Hua⁹⁶, Tomas J. Tanskanen¹⁰⁹, Marta Tojo⁴⁴, David C. Wedge^{1,65,66}, Jorge Zamora^{1,42,43,44}, Jieming Chen^{64,110}, Lauri A. Aaltonen¹¹¹, Gunnar Rätsch^{112,113,114,115,116,117}, Roland F. Schwarz^{7,118,119,120}, Atul J. Butte¹²¹, Alvis Brazma⁷, Peter J. Campbell^{1,2}, Stephen J. Chanock⁹⁶, Nilanjan Chatterjee^{122,123}, Oliver Stegle^{7,8,124}, Olivier Harismendy¹²⁵, G. Steven Bova¹²⁶, Dmitry A. Gordenin⁹⁷, Jose M. C. Tubio^{42,43,44}, Douglas F. Easton^{82,83}, Xavier Estivill^{47,84} & Jan O. Korbel^{7,8}

Relicative immortality David Haan⁹, Lina Sieverling^{127,128}, Lars Feuerbach¹²⁷, Lincoln D. Stein^{12,13} & Joshua M. Stuart⁹

Ethical considerations of genomic cloud computing Don Chalmers¹²⁹, Yann Joly¹³⁰, Bartha Knoppers¹³⁰, Fruzsina Molnár-Gábor¹³¹, Jan O. Korbel^{7,8}, Mark Phillips¹³⁰, Adrian Thorogood¹³⁰ & David Townend¹³⁰

Box 1 ‘Online resources for data access, visualization and analysis’ Mary Goldman¹³², Junjun Zhang¹⁵, Nuno A. Fonseca^{7,133}, Qian Xiang¹⁵, Brian Craft¹³², Elena Piñeiro-Yáñez¹³⁵, Alfonso Muñoz⁷, Robert Petryszak⁷, Anja Füllgrabe⁷, Fatima Al-Shahrour¹³⁵, Maria Keays⁷, David Haussler^{132,136}, John Weinstein^{137,138}, Wolfgang Huber⁸, Alfonso Valencia^{40,76}, Irene Papatheodorou⁷, Jingchun Zhu¹³², Brian D. O’Connor^{15,37}, Lincoln D. Stein^{12,13}, Alvis Brazma⁷, Vincent Ferretti^{15,86} & Miguel Vazquez^{40,41}

Pilot-63 Validation Process L. Jonathan Dursi^{12,25}, Christina K. Yung¹⁵, Matthew H. Bailey^{26,27}, Gordon Saksena³, Keiran M. Raine¹, Ivo Buchhalter^{28,29,30}, Kortine Kleinheinz^{28,30}, Matthias Schlesner^{28,31}, Yu Fan³², David Torrents^{40,76}, Matthias Bieg^{139,140}, Paul C. Boutros^{12,18,20,21}, Ken Chen¹⁴¹, Zechen Chong¹⁴², Kristian Cibulskis³, Oliver Drechsel^{47,49}, Roland Eils^{28,30,143,144}, Robert S. Fulton^{26,27,35}, Josep L. Gelpi^{40,145}, Mark Gerstein^{63,64,69}, Santiago Gonzalez^{7,8}, Gad Getz^{3,4,5,6}, Ivo G. Gut^{49,74}, Faraz Hach^{146,147}, Michael Heinold^{28,30}, Taobo Hu¹⁴⁸, Vincent Huang¹², Barbara Hutter^{140,149,150}, Hyung-Lae Kim⁵⁶, Natalie Jäger²⁸, Jongsun Jung¹⁵¹, Sushant Kumar^{63,64}, Yogesh Kumar¹⁴⁸, Christopher Lalansingh¹², Ignaty Leshchiner³, Ivica Letunic⁶², Dimitri Livitz³, Eric Z. Ma¹⁴⁸, Yosef Maruvka^{3,19,152}, R. Jay Mashl^{27,57}, Michael D. McLellan^{26,27,35}, Ana Milovanovic⁴⁰,

Morten Muhlig Nielsen¹⁵³, Brian D. O'Connor^{15,37}, Stephan Ossowski^{47,48,49}, Nagarajan Paramasivam^{28,140}, Jakob Skou Pedersen^{153,154}, Marc D. Perry^{14,15}, Montserrat Puiggròs⁴⁰, Romina Royo⁴⁰, Esther Rheinbay^{3,6,19}, S. Cenk Sahinalp^{147,155,156}, Iman Sarrafi^{147,156}, Chip Stewart³, Miranda D. Stobbe^{49,74}, Grace Tiao³, Jeremiah A. Wala^{3,6,157}, Jiayin Wang^{27,58,158}, Wenyi Wang³², Sebastian M. Waszak⁸, Joachim Weischenfeldt^{8,99,100}, Michael Wendl^{27,159,160}, Johannes Werner^{28,161}, Zhenggang Wu¹⁴⁸, Hong Xue¹⁴⁸, Sergei Yakneen⁸, Takafumi N. Yamaguchi¹², Kai Ye^{58,59}, Venkata Yellapantula^{67,68}, Junjun Zhang¹⁵, David A. Wheeler^{33,34}, Li Ding^{26,27,35} & Jared T. Simpson^{12,36}

Pilot-63 Processing of Validation Data Christina K. Yung¹⁵, Brian D. O'Connor^{15,37}, Sergei Yakneen⁸, Junjun Zhang¹⁵, Kyle Ellrott³⁸, Kortine Kleinheinz^{28,30}, Naoki Miyoshi³⁹, Keiran M. Raine¹, Romina Royo⁴⁰, Gordon Saksena³, Matthias Schlesner^{28,31}, Solomon I. Shorser¹², Miguel Vazquez^{40,41}, Joachim Weischenfeldt^{8,99,100}, Denis Yuen¹², Adam P. Butler¹, Brandi N. Davis-Dusenberry¹⁶², Roland Eils^{28,30,143,144}, Vincent Ferretti^{15,86}, Robert L. Grossman¹⁶³, Olivier Harismendy¹²⁵, Youngwook Kim^{164,165}, Hidewaki Nakagawa⁸¹, Steven J. Newhouse⁷, David Torrents^{40,76} & Lincoln D. Stein^{12,13}

Whole-genome Sequencing Somatic Variant calling Junjun Zhang¹⁵, Christina K. Yung¹⁵ & Solomon I. Shorser¹²

Whole Genome alignment Keiran M. Raine¹, Junjun Zhang¹⁵ & Brian D. O'Connor^{15,37}

DKFZ Pipeline Kortine Kleinheinz^{28,30}, Tobias Rausch⁸, Jan O. Korbel^{7,8}, Ivo Buchhalter^{28,29,30}, Michael C. Heinold^{28,30}, Barbara Hutter^{140,149,150}, Natalie Jäger²⁸, Nagarajan Paramasivam^{28,140} & Matthias Schlesner^{28,31}

EMBL Pipeline Joachim Weischenfeldt^{8,99,100} & Tobias Rausch⁸

Sanger Pipeline Keiran M. Raine¹, Jonathan Hinton¹, David R. Jones¹, Andrew Menzies¹ & Lucy Stebbings¹

Broad Pipeline Gordon Saksena³, Dimitri Livitz³, Esther Rheinbay^{3,6,19}, Julian M. Hess^{3,152}, Ignaty Leshchiner³, Chip Stewart³, Grace Tiao³, Jeremiah A. Wala^{3,6,157}, Amaro Taylor-Weiner⁹⁰, Mara Rosenberg^{3,19}, Andrew J. Dunford³, Manaswi Gupta³, Marcin Imielinski^{166,167}, Matthew Meyerson^{3,6,157}, Rameen Beroukhim^{3,6,168} & Gad Getz^{3,4,5,6}

MuSE Pipeline Yu Fan³² & Wenyi Wang³²

Consensus Somatic SNV/indel Annotation Andrew Menzies¹, Matthias Schlesner^{28,31}, Jüri Reimand^{12,18}, Priyanka Dhingra^{71,73} & Ekta Khurana^{70,71,72,73}

Somatic SNV and Indel Merging L. Jonathan Dursi^{12,25}, Christina K. Yung¹⁵, Matthew H. Bailey^{26,27}, Gordon Saksena³, Keiran M. Raine¹, Ivo Buchhalter^{28,29,30}, Kortine Kleinheinz^{28,30}, Matthias Schlesner^{28,31}, Yu Fan³², David Torrents^{40,76}, Matthias Bieg^{139,140}, Paul C. Boutros^{12,18,20,21}, Ken Chen¹⁴¹, Zechen Chong¹⁴², Kristian Cibulskis³, Oliver Drechsel^{47,49}, Roland Eils^{28,30,143,144}, Robert S. Fulton^{26,27,35}, Josep L. Gelpí^{40,145}, Mark Gerstein^{63,64,69}, Santiago Gonzalez^{7,8}, Gad Getz^{3,4,5,6}, Ivo G. Gut^{49,74}, Faraz Hach^{146,147}, Michael Heinold^{28,30}, Taobo Hu¹⁴⁸, Vincent Huang¹², Barbara Hutter^{140,149,150}, Hyung-Lae Kim⁵⁶, Natalie Jäger²⁸, Jongsun Jung¹⁵¹, Sushant Kumar^{63,64}, Yogesh Kumar¹⁴⁸, Christopher Lalansingh¹², Ignaty Leshchiner³, Ivica Letunic⁶², Dimitri Livitz³, Eric Z. Ma¹⁴⁸, Yosef Maruvka^{3,19,152}, R. Jay Mashl^{27,57}, Michael D. McLellan^{26,27,35}, Ana Milovanovic⁴⁰, Morten Muhlig Nielsen¹⁵³, Brian D. O'Connor^{15,37}, Stephan Ossowski^{47,48,49}, Nagarajan Paramasivam^{28,140}, Jakob Skou Pedersen^{153,154}, Marc D. Perry^{14,15}, Montserrat Puiggròs⁴⁰, Romina Royo⁴⁰, Esther Rheinbay^{3,6,19}, S.

Cenk Sahinalp^{147,155,156}, Iman Sarrafi^{147,156}, Chip Stewart³, Miranda D. Stobbe^{49,74}, Grace Tiao³, Jeremiah A. Wala^{3,6,157}, Jiayin Wang^{27,58,158}, Wenyi Wang³², Sebastian M. Waszak⁸, Joachim Weischenfeldt^{8,99,100}, Michael Wendl^{27,159,160}, Johannes Werner^{28,161}, Zhenggang Wu¹⁴⁸, Hong Xue¹⁴⁸, Sergei Yakneen⁸, Takafumi N. Yamaguchi¹², Kai Ye^{58,59}, Venkata Yellapantula^{67,68}, Junjun Zhang¹⁵, David A. Wheeler^{33,34}, Li Ding^{26,27,35} & Jared T. Simpson^{12,36}

Somatic SV Merging Joachim Weischenfeldt^{8,99,100}, Francesco Favero¹⁶⁹ & Yilong Li¹

Somatic CNA Merging Stefan Dentro^{1,65,91}, Jeff Wintersinger^{170,171,172} & Ignaty Leshchiner³

Oxidative Artefact Filtration Dimitri Livitz³, Ignaty Leshchiner³, Chip Stewart³, Esther Rheinbay^{3,6,19}, Gordon Saksena³ & Gad Getz^{3,4,5,6}

Strand Bias Filtration Matthias Bieg^{139,140}, Ivo Buchhalter^{28,29,30}, Johannes Werner^{28,161} & Matthias Schlesner^{28,31}

miniBAM Generation Jeremiah Wala^{3,6,157}, Gordon Saksena³, Rameen Beroukhim^{3,6,168} & Gad Getz^{3,4,5,6}

Germline Variant Identification from WGS Tobias Rausch⁸, Grace Tiao³, Sebastian M. Waszak⁸, Bernardo Rodriguez-Martin^{42,43,44}, Suyash Shringarpure⁴⁵, Dai-Ying Wu⁴⁶, Sergei Yakneen⁸, German M. Demidov^{47,48,49}, Olivier Delaneau^{50,51,52}, Shuto Hayashi³⁹, Seiya Imoto³⁹, Nina Habermann⁸, Ayellet V. Segre^{3,53}, Erik Garrison¹, Andy Cafferkey⁷, Eva G. Alvarez^{42,43,44}, Alicia L. Bruzos^{42,43,44}, Jorge Zamora^{1,42,43,44}, José María Heredia-Genestar⁵⁴, Francesc Muyas^{47,48,49}, Oliver Drechsel^{47,49}, L. Jonathan Dursi^{12,25}, Adrian Baez-Ortega⁵⁵, Hyung-Lae Kim⁵⁶, Matthew H. Bailey^{26,27}, R. Jay Mashl^{27,57}, Kai Ye^{58,59}, Ivo Buchhalter^{28,29,30}, Vasilisa Rudneva⁸, Ji Wan Park¹⁷³, Eun Pyo Hong¹⁷³, Seong Gu Heo¹⁷³, Anthony DiBiase⁶⁰, Kuan-lin Huang^{27,61}, Ivica Letunic⁶², Michael D. McLellan^{26,27,35}, Steven J. Newhouse⁷, Matthias Schlesner^{28,31}, Tal Shmaya⁴⁶, Sushant Kumar^{63,64}, David C. Wedge^{1,65,66}, Mark H. Wright⁴⁵, Venkata D. Yellapantula^{67,68}, Mark Gerstein^{63,64,69}, Ekta Khurana^{70,71,72,73}, Tomas Marques-Bonet^{74,75,76,77}, Arcadi Navarro^{74,75,76}, Carlos D. Bustamante^{45,78}, Jared T. Simpson^{12,36}, Li Ding^{26,27,35}, Reiner Siebert^{79,80}, Hidewaki Nakagawa⁸¹, Douglas F. Easton^{82,83}, Stephan Ossowski^{47,48,49}, Jose M. C. Tubio^{42,43,44}, Gad Getz^{3,4,5,6}, Francisco M. De La Vega^{45,46,78} & Xavier Estivill^{47,84} & Jan O. Korbel^{7,8}

RNA-seq Analysis Nuno A. Fonseca^{7,133}, André Kahles^{112,113,114,115,116}, Kjong-Van Lehmann^{112,114,115,174,175}, Lara Urban^{7,8}, Cameron M. Soulette³⁷, Yuichi Shiraishi³⁹, Fenglin Liu^{176,177}, Yao He¹⁷⁶, Deniz Demircioğlu^{178,179}, Natalie R. Davidson^{112,114,115,117,174}, Claudia Calabrese^{7,8}, Junjun Zhang¹⁵, Marc D. Perry^{14,15}, Qian Xiang¹⁵, Liliana Greger⁷, Siliang Li^{180,181}, Dongbing Liu^{180,181}, Stefan G. Stark^{115,174,182,183}, Fan Zhang¹⁷⁶, Samirkumar B. Amin^{184,185,186}, Peter Bailey¹⁸⁷, Aurélien Chateigner¹⁵, Isidro Cortés-Ciriano^{93,94,95}, Brian Craft¹³², Serap Erkek⁸, Milana Frenkel-Morgenstern¹⁸⁸, Mary Goldman¹³², Katherine A. Hoadley^{23,24}, Yong Hou^{180,181}, Matthew R. Huska¹¹⁸, Ekta Khurana^{70,71,72,73}, Helena Kilpinen¹⁸⁹, Jan O. Korbel^{7,8}, Fabien C. Lamaze¹², Chang Li^{180,181}, Xiaobo Li^{180,181}, Xinyue Li¹⁸⁰, Xingmin Liu^{180,181}, Maximillian G. Marin³⁷, Julia Markowski¹¹⁸, Tannistha Nandi¹⁹⁰, Morten Muhlig Nielsen¹⁵³, Akinyemi I. Ojesina^{191,192,193}, Qiang Pan-Hammarström^{180,194}, Peter J. Park^{94,95}, Chandra Sekhar Pedamallu^{3,6,168}, Jakob Pedersen^{153,154}, Reiner Siebert^{79,80}, Hong Su^{180,181}, Patrick Tan^{190,195,196,197}, Bin Tean Teh^{195,196,197,198,199}, Jian Wang¹⁸⁰, Sebastian M. Waszak⁸, Heng Xiong^{180,181}, Sergei Yakneen⁸, Chen Ye^{180,181}, Christina Yung¹⁵, Xiuqing Zhang¹⁸⁰, Liangtao Zheng¹⁷⁶, Jingchun Zhu¹³², Shida Zhu^{180,181}, Philip Awadalla^{12,13}, Chad J. Creighton²⁰⁰, Matthew Meyerson^{3,6,157}, B. F. Francis Ouellette^{16,17}, Kui

Wu^{180,181}, Huanming Yang¹⁸⁰, Jonathan Göke^{178,201}, Roland F. Schwarz^{7,118,119,120}, Oliver Stegle^{7,8,124}, Zemin Zhang^{176,202}, Alvis Brazma⁷, Gunnar Rätsch^{112,113,114,115,116,117} & Angela N. Brooks^{3,37,157}

Clustering of Tumour Genomes Based on Telomere Maintenance-Related Features David Haan⁹, Lincoln D. Stein^{12,13} & Joshua M. Stuart⁹

Clustered Mutational Processes in PCAWG Jonas Demeulemeester^{91,92}, Maxime Tarabichi^{1,91}, Matthew W Fittall⁹¹, Peter J. Campbell^{1,2}, Jan O. Korbel^{7,8} & Peter Van Loo^{91,92}

Tumours Without Detected Driver Mutations Esther Rheinbay^{3,6,19}, Amaro Taylor-Weiner⁹⁰, Radhakrishnan Sabarinathan^{87,88,89}, Peter J. Campbell^{1,2} & Gad Getz^{3,4,5,6}

Panorama of Driver Mutations in Human Cancer Radhakrishnan Sabarinathan^{87,88,89}, Oriol Pich^{87,89}, Iñigo Martincorena¹, Carlota Rubio-Perez^{87,89,203}, Malene Juul¹⁵³, Jeremiah Wala^{3,6,157}, Steven Schumacher^{3,204}, Ofer Shapira^{3,157}, Nikos Sidiropoulos¹⁰⁰, Sebastian M. Waszak⁸, David Tamborero^{87,89}, Loris Mularoni^{87,89}, Esther Rheinbay^{3,6,19}, Henrik Hornshøj¹⁵³, Jordi Deu-Pons^{89,205}, Ferran Muiños^{87,89}, Johanna Bertl^{153,206}, Qianyun Guo¹⁵⁴, Chad J. Creighton²⁰⁰, Joachim Weischenfeldt^{8,99,100}, Jan O. Korbel^{7,8}, Gad Getz^{3,4,5,6}, Peter J. Campbell^{1,2}, Jakob Pedersen^{153,154}, Rameen Beroukhim^{3,6,168} & Abel Gonzalez-Perez^{87,89,207}

Pilot-63 Benchmarking and Validation Exercise, Production Calling and Variant Consensus

Development, and Performance on Previously Validated Samples L. Jonathan Dursi^{12,25}, Christina K. Yung¹⁵, Matthew H. Bailey^{26,27}, Gordon Saksena³, Keiran M. Raine¹, Ivo Buchhalter^{28,29,30}, Kortine Kleinheinz^{28,30}, Matthias Schlesner^{28,31}, Yu Fan³², David Torrents^{40,76}, Matthias Bieg^{139,140}, Paul C. Boutros^{12,18,20,21}, Ken Chen¹⁴¹, Zechen Chong¹⁴², Kristian Cibulskis³, Oliver Drechsel^{47,49}, Roland Eils^{28,30,143,144}, Robert S. Fulton^{26,27,35}, Josep L. Gelpi^{40,145}, Mark Gerstein^{63,64,69}, Santiago Gonzalez^{7,8}, Gad Getz^{3,4,5,6}, Ivo G. Gut^{49,74}, Faraz Hach^{146,147}, Michael Heinold^{28,30}, Taobo Hu¹⁴⁸, Vincent Huang¹², Barbara Hutter^{140,149,150}, Hyung-Lae Kim⁵⁶, Natalie Jäger²⁸, Jongsun Jung¹⁵¹, Sushant Kumar^{63,64}, Yogesh Kumar¹⁴⁸, Christopher Lalansingh¹², Ignaty Leshchiner³, Ivica Letunic⁶², Dimitri Livitz³, Eric Z. Ma¹⁴⁸, Yosef Maruvka^{3,19,152}, R. Jay Mashl^{27,57}, Michael D. McLellan^{26,27,35}, Ana Milovanovic⁴⁰, Morten Muhlig Nielsen¹⁵³, Brian D. O'Connor^{15,37}, Stephan Ossowski^{47,48,49}, Nagarajan Paramasivam^{28,140}, Jakob Skou Pedersen^{153,154}, Marc D. Perry^{14,15}, Montserrat Puiggròs⁴⁰, Romina Royo⁴⁰, Esther Rheinbay^{3,6,19}, S. Cenk Sahinalp^{147,155,156}, Iman Sarrafi^{147,156}, Chip Stewart³, Miranda D. Stobbe^{49,74}, Grace Tiao³, Jeremiah A. Wala^{3,6,157}, Jiayin Wang^{27,58,158}, Wenyi Wang³², Sebastian M. Waszak⁸, Joachim Weischenfeldt^{8,99,100}, Michael Wendt^{27,159,160}, Johannes Werner^{28,161}, Zhenggang Wu¹⁴⁸, Hong Xue¹⁴⁸, Sergei Yakneen⁸, Takafumi N. Yamaguchi¹², Kai Ye^{58,59}, Venkata Yellapantula^{67,68}, Junjun Zhang¹⁵, David A. Wheeler^{33,34}, Li Ding^{26,27,35} & Jared T. Simpson^{12,36}

Production Somatic Variant Calling on the PCAWG Compute Cloud Christina K. Yung¹⁵, Brian D. O'Connor^{15,37}, Sergei Yakneen⁸, Junjun Zhang¹⁵, Kyle Ellrott³⁸, Kortine Kleinheinz^{28,30}, Naoki Miyoshi³⁹, Keiran M. Raine¹, Romina Royo⁴⁰, Gordon Saksena³, Matthias Schlesner^{28,31}, Solomon I. Shorser¹², Miguel Vazquez^{40,41}, Joachim Weischenfeldt^{8,99,100}, Denis Yuen¹², Adam P. Butler¹, Brandi N. Davis-Dusenberry¹⁶², Roland Eils^{28,30,143,144}, Vincent Ferretti^{15,86}, Robert L. Grossman¹⁶³, Olivier Harismendy¹²⁵, Youngwook Kim^{164,165}, Hidewaki Nakagawa⁸¹, Steven J. Newhouse⁷, David Torrents^{40,76} & Lincoln D. Stein^{12,13}

PCAWG data portals Mary Goldman¹³², Junjun Zhang¹⁵, Nuno A. Fonseca^{7,133}, Isidro Cortés-Ciriano^{93,94,95}, Qian Xiang¹³⁴, Brian Craft¹³², Elena Piñeiro-Yáñez¹³⁵, Brian D. O'Connor^{15,37}, Wojciech Bazant⁷, Elisabet

Barrera⁷, Alfonso Muñoz⁷, Robert Petryszak⁷, Anja Füllgrabe⁷, Fatima Al-Shahrour¹³⁵, Maria Keays⁷, David Haussler^{132,136}, John Weinstein^{137,138}, Wolfgang Huber⁸, Alfonso Valencia^{40,76}, Irene Papatheodorou⁷, Jingchun Zhu¹³², Vincent Ferretti^{15,86} & Miguel Vazquez^{40,41}

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Working Groups

PCAWG Steering committee Peter J. Campbell^{1,2}, Gad Getz^{3,4,5,6}, Jan O. Korbel^{7,8}, Lincoln D. Stein^{12,13} & Joshua M. Stuart⁹

PCAWG Executive committee Sultan T. Al-Sedairy²⁰⁸, Axel Aretz²⁰⁹, Cindy Bell²¹⁰, Miguel Betancourt²¹¹, Christiane Buchholz²¹², Fabien Calvo²¹³, Christine Chomienne²¹⁴, Michael Dunn²¹⁵, Stuart Edmonds²¹⁶, Eric Green²¹⁷, Shailja Gupta²¹⁸, Carolyn M. Hutter²¹⁷, Karine Jegalian²¹⁹, Jennifer L. Jennings^{10,11}, Nic Jones²²⁰, Hyung-Lae Kim⁵⁶, Youyong Lu^{221,222,223}, Hitoshi Nakagama²²⁴, Gerd Nettekoven²²⁵, Laura Planko²²⁵, David Scott²²⁰, Tatsuhiro Shibata^{226,227}, Kiyo Shimizu²²⁸, Lincoln D. Stein^{12,13}, Michael R. Stratton¹, Takashi Yugawa²²⁸, Giampaolo Tortora^{229,230}, K. VijayRaghavan²¹⁸, Huanming Yang¹⁸⁰ & Jean C. Zenklusen²³¹

PCAWG Ethics and Legal Working Group Yann Joly¹³⁰, Fruzsina Molnár-Gábor¹³¹, Mark Phillips¹³⁰, Adrian Thorogood¹³⁰, David Townend²³², Don Chalmers¹²⁹ & Bartha M. Knoppers¹³⁰

PCAWG Technical Working Group Brice Aminou¹⁵, Javier Bartolome⁴⁰, Keith A. Boroevich^{81,233}, Rich Boyce⁷, Alvis Brazma⁷, Angela N. Brooks^{3,37,157}, Alex Buchanan³⁸, Ivo Buchhalter^{28,29,30}, Adam P. Butler¹, Niall J. Byrne¹⁵, Andy Cafferkey⁷, Peter J. Campbell^{1,2}, Zhaohong Chen²³⁴, Sungsoon Cho²³⁵, Wan Choi²³⁶, Peter Clapham¹, Brandi N. Davis-Dusenberry¹⁶², Francisco M. De La Vega^{45,46,78}, Jonas Demeulemeester^{91,92}, Michelle T. Dow²³⁴, Lewis Jonathan Dursi^{12,25}, Juergen Eils^{143,144}, Roland Eils^{28,30,143,144}, Kyle Ellrott³⁸, Claudiu Farcaș²³⁴, Nodirjon Fayzullaev¹⁵, Vincent Ferretti^{15,86}, Paul Flícek⁷, Nuno A. Fonseca^{7,133}, Josep L. Gelpí^{40,145}, Gad Getz^{3,4,5,6}, Robert L. Grossman¹⁶³, Olivier Harismendy¹²⁵, Allison P. Heath²³⁷, Michael C. Heinold^{28,30}, Julian M. Hess^{3,152}, Oliver Hofmann²³⁸, Jongwhi H. Hong²³⁹, Thomas J. Hudson^{240,241}, Barbara Hutter^{140,149,150}, Carolyn M. Hutter²¹⁷, Daniel Hübschmann^{30,120,143,242,243}, Seiya Imoto³⁹, Sinisa Ivkovic²⁴⁴, Seung-Hyup Jeon²³⁶, Wei Jiao¹², Jongsun Jung¹⁵¹, Rolf Kabbe²⁸, Andre Kahles^{112,113,114,115,175}, Jules N. A. Kerssemakers²⁸, Hyung-Lae Kim⁵⁶, Hyunghwan Kim²³⁶, Jihoon Kim²⁴⁵, Youngwook Kim^{164,165}, Kortine Kleinheinz^{28,30}, Jan O. Korbel^{7,8}, Michael Koscher²⁴⁶, Antonios Koures²³⁴, Milena Kovacevic²⁴⁴, Chris Lawerenz¹⁴⁴, Ignaty Leshchiner³, Jia Liu²⁴⁷, Dimitri Livitz³, George L. Mihaiescu¹⁵, Sanja Mijalkovic²⁴⁴, Ana Mijalkovic Mijalkovic-Lazic²⁴⁴, Satoru Miyano³⁹, Naoki Miyoshi³⁹, Hardeep K. Nahal-Bose¹⁵, Hidewaki Nakagawa⁸¹, Mia Nastic²⁴⁴, Steven J. Newhouse⁷, Jonathan Nicholson¹, David Ocana⁷, Kazuhiro Ohi³⁹, Lucila Ohno-Machado²³⁴, Larsson Omberg⁸⁵, B. F. Francis Ouellette^{16,17}, Nagarajan Paramasivam^{28,140}, Marc D. Perry^{14,15}, Todd D. Pihl²⁴⁸, Manuel Prinz²⁸, Montserrat Puiggròs⁴⁰, Petar Radovic²⁴⁴, Keiran M. Raine¹, Esther Rheinbay^{3,6,19}, Mara Rosenberg^{3,19}, Romina Royo⁴⁰, Gunnar Rätsch^{112,113,114,115,116,117}, Gordon Saksena³, Matthias Schlesner^{28,31}, Solomon I. Shorser¹², Charles Short⁷, Heidi J. Sofia²¹⁷, Jonathan Spring¹⁶³, Adam J. Struck³⁸, Grace Tiao³, Nebojsa Tijanic²⁴⁴, David Torrents^{40,76}, Peter Van Loo^{91,92}, Miguel Vazquez^{40,41}, David Vicente⁴⁰, Jeremiah A. Wala^{3,6,157}, Zhining Wang²³¹, Sebastian M. Waszak⁸, Joachim Weischenfeldt^{8,99,100}, Johannes Werner^{28,161}, Ashley Williams²³⁴, Youngchoon Woo²³⁶, Adam J. Wright¹², Qian Xiang¹³⁴, Liming Yang²³¹, Denis Yuen¹², Brian D. O'Connor^{15,37}, Lincoln D. Stein^{12,13}, Sergei Yakneen⁸, Christina K. Yung¹⁵ & Junjun Zhang¹⁵

PCAWG Reference Annotations Working Group Angela N. Brooks^{3,37,157}, Ivo Buchhalter^{28,29,30}, Peter J. Campbell^{1,2}, Priyanka Dhingra^{71,73}, Lars Feuerbach¹²⁷, Mark Gerstein^{63,64,69}, Gad Getz^{3,4,5,6}, Mark P. Hamilton²⁴⁹, Henrik Hornshøj¹⁵³, Todd A. Johnson²³³, Andre Kahles^{112,113,114,115,175}, Abdullah Kahraman^{250,251,252}, Manolis Kellis^{3,253}, Jan O. Korbel^{7,8}, Morten Muhlig Nielsen¹⁵³, Jakob Skou Pedersen^{153,154}, Paz Polak^{3,4,6}, Jüri Reimand^{12,18}, Esther Rheinbay^{3,6,19}, Nicola D. Roberts¹, Gunnar Rätsch^{112,113,114,115,116,117}, Richard Sallari³, Nasa Sinnott-Armstrong^{3,45}, Alfonso Valencia^{40,76}, Miguel Vazquez^{40,41}, Sebastian M. Waszak⁸, Joachim Weischenfeldt^{8,99,100}, Christian von Mering^{252,254} & Ekta Khurana^{70,71,72,73}

PCAWG Quality-Control Working Group Sergi Beltran^{49,74}, Ivo Buchhalter^{28,29,30}, Peter J. Campbell^{1,2}, Roland Eils^{28,30,143,144}, Daniela S. Gerhard²⁵⁵, Gad Getz^{3,4,5,6}, Marta Gut^{49,74}, Barbara Hutter^{140,149,150}, Daniel Hübschmann^{30,120,143,242,243}, Kortine Kleinheinz^{28,30}, Jan O. Korbel^{7,8}, Dimitri Livitz³, Marc D. Perry^{14,15}, Keiran M. Raine¹, Esther Rheinbay^{3,6,19}, Mara Rosenberg^{3,19}, Gordon Saksena³, Matthias Schlesner^{28,31}, Miranda D. Stobbe^{49,74}, Jean-Rémi Trotta⁷⁴, Johannes Werner^{28,161}, Justin P. Whalley⁷⁴ & Ivo G. Gut^{49,74}

PCAWG SNV Calling Working Group Matthew H. Bailey^{26,27}, Beifang Niu²⁵⁶, Matthias Bieg^{139,140}, Paul C. Boutros^{12,18,20,21}, Ivo Buchhalter^{28,29,30}, Adam P. Butler¹, Ken Chen¹⁴¹, Zechen Chong¹⁴², Oliver Drechsel^{47,49}, Lewis Jonathan Dursi^{12,25}, Roland Eils^{28,30,143,144}, Kyle Ellrott³⁸, Shadrielle M. G. Espiritu¹², Yu Fan³², Robert S. Fulton^{26,27,35}, Shengjie Gao¹⁸⁰, Josep L. Gelpí^{40,145}, Mark Gerstein^{63,64,69}, Gad Getz^{3,4,5,6}, Santiago Gonzalez^{7,8}, Ivo G. Gut^{49,74}, Faraz Hach^{146,147}, Michael C. Heinold^{28,30}, Julian M. Hess^{3,152}, Jonathan Hinton¹, Taobo Hu¹⁴⁸, Vincent Huang¹², Yi Huang^{158,257}, Barbara Hutter^{140,149,150}, David R. Jones¹, Jongsun Jung¹⁵¹, Natalie Jäger²⁸, Hyung-Lae Kim⁵⁶, Kortine Kleinheinz^{28,30}, Sushant Kumar^{63,64}, Yogesh Kumar¹⁴⁸, Christopher M. Lalansingh¹², Ignaty Leshchiner³, Ivica Letunic⁶², Dimitri Livitz³, Eric Z. Ma¹⁴⁸, Yosef E. Maruvka^{3,19,152}, R. Jay Mashl^{27,57}, Michael D. McLellan^{26,27,35}, Andrew Menzies¹, Ana Milovanovic⁴⁰, Morten Muhlig Nielsen¹⁵³, Stephan Ossowski^{47,48,49}, Nagarajan Paramasivam^{28,140}, Jakob Skou Pedersen^{153,154}, Marc D. Perry^{14,15}, Montserrat Puiggròs⁴⁰, Keiran M. Raine¹, Esther Rheinbay^{3,6,19}, Romina Royo⁴⁰, S. Cenk Sahinalp^{147,155,156}, Gordon Saksena³, Iman Sarrafi^{147,156}, Matthias Schlesner^{28,31}, Lucy Stebbings¹, Chip Stewart³, Miranda D. Stobbe^{49,74}, Jon W. Teague¹, Grace Tiao³, David Torrents^{40,76}, Jeremiah A. Wala^{3,6,157}, Jiayin Wang^{27,58,158}, Wenyi Wang³², Sebastian M. Waszak⁸, Joachim Weischenfeldt^{8,99,100}, Michael C. Wendt^{27,159,160}, Johannes Werner^{28,161}, David A. Wheeler^{33,34}, Zhenggang Wu¹⁴⁸, Hong Xue¹⁴⁸, Sergei Yakneen⁸, Takafumi N. Yamaguchi¹², Kai Ye^{58,59}, Venkata D. Yellapantula^{67,68}, Christina K. Yung¹⁵, Junjun Zhang¹⁵, Li Ding^{26,27,35} & Jared T. Simpson^{12,36}

PCAWG Drivers and Functional Interpretation Working Group Federico Abascal¹, Samirkumar B. Amin^{184,185,186}, Gary D. Bader¹³, Pratiti Bandopadhyay^{3,258,259}, Jonathan Barenboim¹², Rameen Beroukhim^{3,6,168}, Johanna Bertl^{153,206}, Keith A. Boroevich^{81,233}, Søren Brunak^{260,261}, Peter J. Campbell^{1,2}, Joana Carlevaro-Fita^{262,263,264}, Dimple Chakravarty^{265,266}, Calvin Wing Yiu Chan^{28,128}, Ken Chen¹⁴¹, Jung Kyoon Choi²⁶⁷, Jordi Deu-Pons^{89,205}, Priyanka Dhingra^{71,73}, Klev Diamanti²⁶⁸, Lars Feuerbach¹²⁷, J. Lynn Fink^{40,269}, Nuno A. Fonseca^{7,133}, Joan Frigola²⁰⁵, Carlo Gambacorti-Passerini²⁷⁰, Dale W. Garsed²⁷¹, Qianyun Guo¹⁵⁴, Ivo G. Gut^{49,74}, David Haan⁹, Mark P. Hamilton²⁴⁹, Nicholas J. Haradhvala^{3,19}, Arif O. Harmancı^{64,272}, Mohamed Helmy¹⁷¹, Carl Herrmann^{28,30,273}, Julian M. Hess^{3,152}, Asger Hobolth^{154,206}, Ermin Hodzic¹⁵⁶, Chen Hong^{127,128}, Henrik Hornshøj¹⁵³, Keren Isaev^{12,18}, Jose M. G. Izarzugaza²⁶⁰, Rory Johnson^{263,274}, Todd A. Johnson²³³, Malene Juul¹⁵³, Randi Istrup Juul¹⁵³, Andre Kahles^{112,113,114,115,175}, Abdullah Kahraman^{250,251,252}, Manolis Kellis^{3,253}, Ekta Khurana^{70,71,72,73}, Jaegil Kim³, Jong K. Kim²⁷⁵, Youngwook Kim^{164,165}, Jan Komorowski^{268,276}, Jan O. Korbel^{7,8},

Sushant Kumar^{63,64}, Andrés Lanzós^{263,264,274}, Erik Larsson¹¹², Donghoon Lee⁶⁴, Kjong-Van Lehmann^{112,114,115,174,175}, Shantao Li⁶⁴, Xiaotong Li⁶⁴, Ziao Lin^{3,277}, Eric Minwei Liu^{71,73,278}, Lucas Lochovsky^{63,64,186}, Shaoke Lou^{63,64}, Tobias Madsen¹⁵³, Kathleen Marchal^{279,280}, Iñigo Martincorena¹, Alexander Martinez-Fundichely^{71,72,73}, Yosef E. Maruvka^{3,19,152}, Patrick D. McGillivray⁶³, William Meyerson^{64,281}, Ferran Muñoz^{87,89}, Loris Mularoni^{87,89}, Hidewaki Nakagawa⁸¹, Morten Muhlig Nielsen¹⁵³, Marta Paczkowska¹², Keunchil Park^{282,283}, Kiejung Park²⁸⁴, Tirso Pons²⁸⁵, Sergio Pulido-Tamayo^{279,280}, Jüri Reimand^{12,18}, Iker Reyes-Salazar⁸⁷, Matthew A. Reyna²⁸⁶, Esther Rheinbay^{3,6,19}, Mark A. Rubin^{274,287,288,289,290}, Carlota Rubio-Perez^{87,89,203}, S. Cenk Sahinalp^{147,155,156}, Gordon Saksena³, Leonidas Salichos^{63,64}, Chris Sander^{112,157,291,292}, Steven E. Schumacher^{3,204}, Mark Shackleton²⁷¹, Ofer Shapira^{3,157}, Ciyou Shen^{292,293}, Raunak Shrestha¹⁴⁷, Shimin Shuai^{12,13}, Nikos Sidiropoulos¹⁰⁰, Lina Sieverling^{127,128}, Nasa Sinnott-Armstrong^{3,45}, Lincoln D. Stein^{12,13}, David Tamborero^{87,89}, Grace Tiao³, Tatsuhiko Tsunoda^{233,294,295,296}, Husen M. Umer^{268,297}, Liis Uusküla-Reimand^{298,299}, Alfonso Valencia^{40,76}, Miguel Vazquez^{40,41}, Lieven P. C. Verbeke^{280,300}, Claes Wadelius³⁰¹, Lina Wadi¹², Jiayin Wang^{27,58,158}, Jonathan Warrell^{63,64}, Sebastian M. Waszak⁸, Joachim Weischenfeldt^{8,99,100}, Guanming Wu³⁰², Jun Yu³⁰³, Jing Zhang⁶⁴, Xuanping Zhang^{158,304}, Yan Zhang^{64,305,306}, Zhongming Zhao³⁰⁷, Lihua Zou³⁰⁸, Christian von Mering^{252,254}, Mark Gerstein^{63,64,69}, Gad Getz^{3,4,5,6}, Michael S. Lawrence^{3,19,233}, Jakob Skou Pedersen^{153,154}, Benjamin J. Raphael²⁸⁶, Joshua M. Stuart⁹ & David A. Wheeler^{33,34}

PCAWG Transcriptome Working Group Samirkumar B. Amin^{184,185,186}, Philip Awadalla^{12,13}, Peter J. Bailey¹⁸⁷, Claudia Calabrese^{7,8}, Aurélien Chateigner¹⁵, Isidro Cortés-Ciriano^{93,94,95}, Brian Craft¹³², David Craft^{3,309}, Chad J. Creighton²⁰⁰, Natalie R. Davidson^{112,114,115,117,174}, Deniz Demircioğlu^{178,179}, Serap Erkek⁸, Nuno A. Fonseca^{7,133}, Milana Frenkel-Morgenstern¹⁸⁸, Mary J. Goldman¹³², Liliana Greger⁷, Jonathan Göke^{178,201}, Yao He¹⁷⁶, Katherine A. Hoadley^{23,24}, Yong Hou^{180,181}, Matthew R. Huska¹¹⁸, Andre Kahles^{112,113,114,115,175}, Ekta Khurana^{70,71,72,73}, Helena Kilpinen¹⁸⁹, Jan O. Korbel^{7,8}, Fabien C. Lamaze¹², Kjong-Van Lehmann^{112,114,115,174,175}, Chang Li^{180,181}, Siliang Li^{180,181}, Xiaobo Li^{180,181}, Xinyue Li¹⁸⁰, Dongbing Liu^{180,181}, Fenglin Liu^{176,177}, Xingmin Liu^{180,181}, Maximillian G. Marin³⁷, Julia Markowski¹¹⁸, Matthew Meyerson^{3,6,157}, Tannistha Nandi¹⁹⁰, Morten Muhlig Nielsen¹⁵³, Akinyemi I. Ojesina^{191,192,193}, B. F. Francis Ouellette^{16,17}, Qiang Pan-Hammarström^{180,194}, Peter J. Park^{94,95}, Chandra Sekhar Pedamallu^{3,6,168}, Jakob Skou Pedersen^{153,154}, Marc D. Perry^{14,15}, Roland F. Schwarz^{7,118,119,120}, Yuichi Shiraishi³⁹, Reiner Siebert^{79,80}, Cameron M. Soulette³⁷, Stefan G. Stark^{115,174,182,183}, Oliver Stegle^{7,8,124}, Hong Su^{180,181}, Patrick Tan^{190,195,196,197}, Bin Tean Teh^{195,196,197,198,199}, Lara Urban^{7,8}, Jian Wang¹⁸⁰, Sebastian M. Waszak⁸, Kui Wu^{180,181}, Qian Xiang¹³⁴, Heng Xiong^{180,181}, Sergei Yakneen⁸, Huanming Yang¹⁸⁰, Chen Ye^{180,181}, Christina K. Yung¹⁵, Fan Zhang¹⁷⁶, Junjun Zhang¹⁵, Xiuqing Zhang¹⁸⁰, Zemin Zhang^{176,202}, Liangtao Zheng¹⁷⁶, Jingchun Zhu¹³², Shida Zhu^{180,181}, Alvis Brazma⁷, Angela N. Brooks^{3,37,157} & Gunnar Rätsch^{112,113,114,115,116,117}

PCAWG Epigenome Working Group Hiroyuki Aburatani³¹⁰, Hans Binder^{311,312}, Huy Q. Dinh³¹³, Lars Feuerbach¹²⁷, Shengjie Gao¹⁸⁰, Ivo G. Gut^{49,74}, Simon C. Heath^{49,74}, Steve Hoffmann^{311,312,314,315}, Charles David Imbusch¹²⁷, Ekta Khurana^{70,71,72,73}, Helene Kretzmer^{312,315}, Peter W. Laird³¹⁶, Jose I. Martin-Subero^{76,317}, Genta Nagae^{310,318}, Paz Polak^{3,4,6}, Hui Shen³¹⁹, Reiner Siebert^{79,80}, Nasa Sinnott-Armstrong^{3,45}, Miranda D. Stobbe^{49,74}, Qi Wang²⁴⁶, Dieter Weichenhan³²⁰, Sergei Yakneen⁸, Wanding Zhou³¹⁹, Benjamin P. Berman^{313,321,322}, Benedikt Brors^{127,150,323} & Christoph Plass³²⁰

PCAWG Structural Variation Working Group Kadir C. Akdemir¹⁴¹, Eva G. Alvarez^{42,43,44}, Adrian Baez-Ortega⁵⁵, Paul C. Boutros^{12,18,20,21}, David D. L. Bowtell²⁷¹, Benedikt Brors^{127,150,323}, Kathleen H. Burns^{324,325}, John Busanovich^{3,326}, Kin Chan³²⁷, Ken Chen¹⁴¹, Isidro Cortés-Ciriano^{93,94,95}, Ana Dueso-Barroso⁴⁰, Andrew J. Dunford³, Paul A. Edwards^{328,329}, Xavier Estivill^{47,84}, Dariush Etemadmoghadam²⁷¹, Lars Feuerbach¹²⁷, J. Lynn Fink^{40,269}, Milana Frenkel-Morgenstern¹⁸⁸, Dale W. Garsed²⁷¹, Mark Gerstein^{63,64,69}, Dmitry A. Gordenin⁹⁷, David Haan⁹, James E. Haber³³⁰, Julian M. Hess^{3,152}, Barbara Hutter^{140,149,150}, Marcin Imielinski^{166,167}, David T. W. Jones^{331,332}, Young Seok Ju^{1,267}, Marat D. Kazanov^{333,334,335}, Leszek J. Klimczak⁹⁸, Youngil Koh^{336,337}, Jan O. Korbel^{7,8}, Kiran Kumar³, Eunjung Alice Lee³³⁸, Jake June-Koo Lee^{94,95}, Yilong Li¹, Andy G. Lynch^{328,329,339}, Geoff Macintyre³²⁸, Florian Markowetz^{328,329}, Iñigo Martincorena¹, Alexander Martinez-Fundichely^{71,72,73}, Matthew Meyerson^{3,6,157}, Satoru Miyano³⁹, Hidewaki Nakagawa⁸¹, Fabio C. P. Navarro⁶³, Stephan Ossowski^{47,48,49}, Peter J. Park^{94,95}, John V. Pearson^{340,341}, Montserrat Puiggrós⁴⁰, Karsten Rippe¹²⁰, Nicola D. Roberts¹, Steven A. Roberts¹⁰⁷, Bernardo Rodriguez-Martin^{42,43,44}, Steven E. Schumacher^{3,204}, Ralph Scully³⁴², Mark Shackleton²⁷¹, Nikos Sidiropoulos¹⁰⁰, Lina Sieverling^{127,128}, Chip Stewart³, David Torrents^{40,76}, Jose M. C. Tubio^{42,43,44}, Izar Villasante⁴⁰, Nicola Waddell^{340,341}, Jeremiah A. Wala^{3,6,157}, Joachim Weischenfeldt^{8,99,100}, Lixing Yang³⁴³, Xiaotong Yao^{166,344}, Sung-Soo Yoon³³⁷, Jorge Zamora^{1,42,43,44}, Cheng-Zhong Zhang^{3,6,157}, Rameen Beroukhim^{3,6,168} & Peter J. Campbell^{1,2}

PCAWG Mutational Signatures Working Group Ludmil B. Alexandrov^{1,101}, Erik N. Bergstrom³⁴⁵, Arnoud Boot^{196,346}, Paul C. Boutros^{12,18,20,21}, Kin Chan³²⁷, Kyle Covington³⁴, Akihiro Fujimoto⁸¹, Gad Getz^{3,4,5,6}, Dmitry A. Gordenin⁹⁷, Nicholas J. Haradhvala^{3,19}, Mi Ni Huang^{196,346}, S. M. Ashiquul Islam¹⁰¹, Marat D. Kazanov^{333,334,335}, Jaegil Kim³, Leszek J. Klimczak⁹⁸, Michael S. Lawrence^{3,19,233}, Iñigo Martincorena¹, John R. McPherson^{196,346}, Sandro Morganella¹, Ville Mustonen^{347,348,349}, Hidewaki Nakagawa⁸¹, Alvin Wei Tian Ng³⁵⁰, Paz Polak^{3,4,6}, Stephenie D. Prokopec¹², Steven A. Roberts¹⁰⁷, Radhakrishnan Sabarinathan^{87,88,89}, Natalie Saini⁹⁷, Tatsuhiro Shibata^{226,227}, Yuichi Shirashi³⁹, Ignacio Vázquez-García^{1,67,354,355}, Yang Wu^{196,346}, Fouad Yousif¹², Willie Yu³⁵⁶, Steven G. Rozen^{196,197,346}, Michael R. Stratton¹ & Bin Tean Teh^{195,196,197,198,199}

PCAWG Germline Cancer Genome Working Group Ludmil B. Alexandrov^{1,101}, Eva G. Alvarez^{42,43,44}, Adrian Baez-Ortega⁵⁵, Matthew H. Bailey^{26,27}, Mattia Bosio^{40,47,49}, G. Steven Bova¹²⁶, Alvis Brazma⁷, Alicia L. Bruzos^{42,43,44}, Ivo Buchhalter^{28,29,30}, Carlos D. Bustamante^{45,78}, Atul J. Butte¹²¹, Andy Cafferkey⁷, Claudia Calabrese^{7,8}, Peter J. Campbell^{1,2}, Stephen J. Chanock⁹⁶, Nilanjan Chatterjee^{122,123}, Jieming Chen^{64,110}, Francisco M. De La Vega^{45,46,78}, Olivier Delaneau^{50,51,52}, German M. Demidov^{47,48,49}, Anthony DiBiase⁶⁰, Li Ding^{26,27,35}, Oliver Drechsler^{47,49}, Lewis Jonathan Dursi^{12,25}, Douglas F. Easton^{82,83}, Serap Erkek⁸, Georgia Escaramis^{47,103,104}, Erik Garrison¹, Mark Gerstein^{63,64,69}, Gad Getz^{3,4,5,6}, Dmitry A. Gordenin⁹⁷, Nina Habermann⁸, Olivier Harismendy¹²⁵, Eoghan Harrington¹⁰⁵, Shuto Hayashi³⁹, Seong Gu Heo¹⁷³, José María Heredia-Genestar⁵⁴, Aliaksei Z. Holik⁴⁷, Eun Pyo Hong¹⁷³, Xing Hua⁹⁶, Kuan-lin Huang^{27,61}, Seiya Imoto³⁹, Sissel Juul¹⁰⁵, Ekta Khurana^{70,71,72,73}, Hyung-Lae Kim⁵⁶, Youngwook Kim^{164,165}, Leszek J. Klimczak⁹⁸, Roelof Koster¹⁰⁸, Sushant Kumar^{63,64}, Ivica Letunic⁶², Yilong Li¹, Tomas Marques-Bonet^{74,75,76,77}, R. Jay Mashl^{27,57}, Simon Mayes¹⁰⁶, Michael D. McLellan^{26,27,35}, Lisa Mirabello⁹⁶, Francesc Muyas^{47,48,49}, Hidewaki Nakagawa⁸¹, Arcadi Navarro^{74,75,76}, Steven J. Newhouse⁷, Stephan Ossowski^{47,48,49}, Ji Wan Park¹⁷³, Esa Pitkänen⁸, Aparna Prasad⁴⁹, Raquel Rabionet^{47,49,102}, Benjamin Raeder⁸, Tobias Rausch⁸, Steven A. Roberts¹⁰⁷, Bernardo Rodriguez-Martin^{42,43,44}, Vasilisa A. Rudneva⁸, Gunnar Rätsch^{112,113,114,115,116,117}, Natalie Saini⁹⁷, Matthias Schlesner^{28,31}, Roland F. Schwarz^{7,118,119,120}, Ayellet V. Segre^{3,53}, Tal Shmaya⁴⁶, Suyash S. Shringarpure⁴⁵, Nikos

Sidiropoulos¹⁰⁰, Reiner Siebert^{79,80}, Jared T. Simpson^{12,36}, Lei Song⁹⁶, Oliver Stegle^{7,8,124}, Hana Susak^{47,49}, Tomas J. Tanskanen¹⁰⁹, Grace Tiao³, Marta Tojo⁴⁴, Jose M. C. Tubio^{42,43,44}, Daniel J. Turner¹⁰⁶, Lara Urban^{7,8}, Sebastian M. Waszak⁸, David C. Wedge^{1,65,66}, Joachim Weischenfeldt^{8,99,100}, David A. Wheeler^{33,34}, Mark H. Wright⁴⁵, Dai-Ying Wu⁴⁶, Tian Xia³⁵⁷, Sergei Yakneen⁸, Kai Ye^{58,59}, Venkata D. Yellapantula^{67,68}, Jorge Zamora^{1,42,43,44}, Bin Zhu⁹⁶, Xavier Estivill^{47,84} & Jan O. Korbel^{7,8}

PCAWG Pathology and Clinical Correlates Working Group Fatima Al-Shahrour¹³⁵, Gurnit Atwal^{12,13,172}, Peter J. Bailey¹⁸⁷, Paul C. Boutros^{12,18,20,21}, Peter J. Campbell^{1,2}, David K. Chang^{187,358}, Susanna L. Cooke¹⁸⁷, Vikram Deshpande¹⁹, Bishoy M. Faltas¹¹⁷, William C. Faquin¹⁹, Gad Getz^{3,4,5,6}, Syed Haider¹², Wei Jiao¹², Vera B. Kaiser³⁵⁹, Rosa Karlić³⁶⁰, Mamoru Kato³⁶¹, Kirsten Kübler^{3,6,19}, Alexander J. Lazar²², Constance H. Li^{12,18}, David N. Louis¹⁹, Adam Margolin³⁸, Sancha Martin^{1,362}, Hardeep K. Nahal-Bose¹⁵, G. Petur Nielsen¹⁹, Serena Nik-Zainal^{1,351,352,353}, Larsson Omberg⁸⁵, Christine P'ng¹², Marc D. Perry^{14,15}, Paz Polak^{3,4,6}, Esther Rheinbay^{3,6,19}, Mark A. Rubin^{274,287,288,289,290}, Colin A. Semple³⁵⁹, Dennis C. Sgroi¹⁹, Tatsuhiro Shibata^{226,227}, Reiner Siebert^{79,80}, Jaclyn Smith³⁸, Miranda D. Stobbe^{49,74}, Ren X. Sun¹², Kevin Thai¹⁵, Derek W. Wright^{363,364}, Chin-Lee Wu¹⁹, Ke Yuan^{328,362,365}, Junjun Zhang¹⁵, Andrew V. Biankin^{187,358,366,367}, Levi Garraway¹⁵⁷, Sean M. Grimmond³⁶⁸, Katherine A. Hoadley^{23,24} & Lincoln D. Stein^{12,13}

PCAWG Evolution & Heterogeneity Working Group David J. Adams¹, Pavana Anur³⁶⁹, Rameen Beroukhim^{3,6,168}, Paul C. Boutros^{12,18,20,21}, David D. L. Bowtell²⁷¹, Peter J. Campbell^{1,2}, Shaolong Cao³², Elizabeth L. Christie²⁷¹, Marek Cmero^{370,371,372}, Yupeng Cun³⁷³, Kevin J. Dawson¹, Jonas Demeulemeester^{91,92}, Stefan C. Dentro^{1,65,91}, Amit G. Deshwar³⁷⁴, Nilgun Donmez^{147,156}, Ruben M. Drews³²⁸, Roland Eils^{28,30,143,144}, Yu Fan³², Matthew W. Fittall⁹¹, Dale W. Garsed²⁷¹, Moritz Gerstung^{7,8}, Gad Getz^{3,4,5,6}, Santiago Gonzalez^{7,8}, Gavin Ha³, Kerstin Haase⁹¹, Marcin Imielinski^{166,167}, Lara Jerman^{8,375}, Yuan Ji^{376,377}, Clemency Jolly⁹¹, Kortine Kleinheinz^{28,30}, Juhee Lee³⁷⁸, Henry Lee-Six¹, Ignaty Leshchiner³, Dimitri Livitz³, Geoff Macintyre³²⁸, Salem Malikic^{147,156}, Florian Markowetz^{328,329}, Iñigo Martincorena¹, Thomas J. Mitchell^{1,329,379}, Quaid D. Morris^{172,380}, Ville Mustonen^{347,348,349}, Layla Oesper³⁸¹, Martin Peifer³⁷³, Myron Peto³⁸², Benjamin J. Raphael²⁸⁶, Daniel Rosebrock³, Yulia Rubanova^{36,172}, S. Cenk Sahinalp^{147,155,156}, Adriana Salcedo¹², Matthias Schlesner^{28,31}, Steven E. Schumacher^{3,204}, Subhajit Sengupta³⁸³, Ruian Shi³⁸⁰, Seung Jun Shin¹⁸³, Oliver Spiro³, Lincoln D. Stein^{12,13}, Maxime Tarabichi^{1,91}, Shankar Vembu^{380,384}, Ignacio Vázquez-García^{1,67,354,355}, Wenyi Wang³², David A. Wheeler^{33,34}, Jeffrey A. Wintersinger^{170,171,172}, Tsun-Po Yang³⁷³, Xiaotong Yao^{166,344}, Kaixian Yu³⁸⁵, Ke Yuan^{328,362,365}, Hongtu Zhu^{386,387}, Paul T. Spellman³⁸⁸, Peter Van Loo^{91,92} & David C. Wedge^{1,65,66}

PCAWG Portals and Visualization Working Group Fatima Al-Shahrour¹³⁵, Elisabet Barrera⁷, Wojciech Bazant⁷, Alvis Brazma⁷, Isidro Cortés-Ciriano^{93,94,95}, Brian Craft¹³², David Craft^{3,309}, Vincent Ferretti^{15,86}, Nuno A. Fonseca^{7,133}, Anja Füllgrabe⁷, Mary J. Goldman¹³², Wolfgang Huber⁸, Maria Keays⁷, Alfonso Muñoz⁷, Brian D. O'Connor^{15,37}, Irene Papathodorou⁷, Robert Petryszak⁷, Elena Piñeiro-Yáñez¹³⁵, Alfonso Valencia^{40,76}, John N. Weinstein^{137,138}, Qian Xiang¹³⁴, Junjun Zhang¹⁵, David Haussler^{132,136}, Miguel Vazquez^{40,41} & Jingchun Zhu¹³²

PCAWG Mitochondrial Genome and Immunogenomics Working Group Peter J. Campbell^{1,2}, Yiwen Chen³², Chad J. Creighton²⁰⁰, Li Ding^{26,27,35}, Akihiro Fujimoto⁸¹, Masashi Fujita⁸¹, Gad Getz^{3,4,5,6}, Leng Han³⁰⁴, Takanori Hasegawa³⁹, Shuto Hayashi³⁹, Seiya Imoto³⁹, Young Seok Ju^{1,267}, Hyung-Lae Kim⁵⁶, Youngwook Kim^{164,165}, Youngil Koh^{336,337}, Mitsuhiro Komura³⁹, Jun Li³², Iñigo Martincorena¹, Satoru Miyano³⁹, Shinichi

Mizuno³⁸⁹, Keunchil Park^{282,283}, Eigo Shimizu³⁹, Yumeng Wang^{32,390}, John N. Weinstein^{137,138}, Yanxun Xu³⁹¹, Rui Yamaguchi³⁹, Fan Yang³⁸⁰, Yang Yang³⁰⁴, Christopher J. Yoon²⁶⁷, Sung-Soo Yoon³³⁷, Yuan Yuan³², Fan Zhang¹⁷⁶, Zemin Zhang^{176,202}, Han Liang³² & Hidewaki Nakagawa⁸¹

PCAWG Pathogens Working Group Malik Alawi^{392,393}, Ivan Borozan¹², Daniel S. Brewer^{394,395}, Colin S. Cooper^{395,396,397}, Nikita Desai¹⁵, Roland Eils^{28,30,143,144}, Vincent Ferretti^{15,86}, Adam Grundhoff^{392,398}, Murat Iskar³⁹⁹, Kortine Kleinheinz^{28,30}, Hidewaki Nakagawa⁸¹, Akinyemi I. Ojesina^{191,192,193}, Chandra Sekhar Pedamallu^{3,6,168}, Matthias Schlesner^{28,31}, Xiaoping Su⁴⁰⁰, Marc Zapatka³⁹⁹ & Peter Lichter^{149,399}

Providers of tumour-sequencing data

Tumour-specific providers (ovarian cancer) in Australia Kathryn Alsop²⁷¹, Timothy J. C. Bruxner²⁶⁹, Angelika N. Christ²⁶⁹, Elizabeth L. Christie²⁷¹, Stephen M. Cordner⁴⁰³, Prue A. Cowin⁴⁰¹, Ronny Drapkin⁴⁰⁴, Dariush Etemadmoghadam²⁷¹, Sian Fereday⁴⁰¹, Dale W. Garsed²⁷¹, Joshy George¹⁸⁶, Sean M. Grimmond³⁶⁸, Anne Hamilton⁴⁰¹, Oliver Holmes^{340,341}, Jillian A. Hung^{405,406}, Karin S. Kassahn^{269,407}, Stephen H. Kazakoff^{340,341}, Catherine J. Kennedy^{408,409}, Conrad R. Leonard^{340,341}, Linda Mileshkin²⁷¹, David K. Miller^{269,358,410}, Gisela Mir Arnau⁴⁰¹, Chris Mitchell⁴⁰¹, Felicity Newell^{340,341}, Katia Nones^{340,341}, Ann-Marie Patch^{340,341}, John V. Pearson^{340,341}, Michael C. Quinn^{340,341}, Mark Shackleton²⁷¹, Darrin F. Taylor²⁶⁹, Heather Thorne⁴⁰¹, Nadia Traficante⁴⁰¹, Ravikiran Vedururu⁴⁰¹, Nick M. Waddell³⁴¹, Nicola Waddell^{340,341}, Paul M. Waring⁴¹¹, Scott Wood^{340,341}, Qinying Xu^{340,341}, Anna deFazio^{412,413,414} & David D. L. Bowtell²⁷¹

Tumour-specific providers (pancreatic cancer) in Australia Matthew J. Anderson²⁶⁹, Davide Antonello⁴¹⁵, Andrew P. Barbour^{416,417}, Claudio Bassi⁴¹⁵, Samantha Bersani⁴¹⁸, Timothy J. C. Bruxner²⁶⁹, Ivana Cataldo^{418,419}, David K. Chang^{187,358}, Lorraine A. Chantrill^{358,420}, Yoke-Eng Chiew⁴¹², Angela Chou^{358,421}, Angelika N. Christ²⁶⁹, Sara Cingarlini²²⁹, Nicole Cloonan⁴²², Vincenzo Corbo^{419,423}, Maria Vittoria Davi⁴²⁴, Fraser R. Duthie^{187,425}, J. Lynn Fink^{40,269}, Anthony J. Gill^{358,421}, Janet S. Graham^{187,426}, Ivon Harliwong²⁶⁹, Oliver Holmes^{340,341}, Nigel B. Jamieson^{187,367,427}, Amber L. Johns^{358,410}, Karin S. Kassahn^{269,407}, Stephen H. Kazakoff^{340,341}, James G. Kench^{358,421,428}, Luca Landoni⁴¹⁵, Rita T. Lawlor⁴¹⁹, Conrad R. Leonard^{340,341}, Andrea Mafficini⁴¹⁹, Neil D. Merrett^{415,429}, David K. Miller^{269,358,410}, Marco Miotto⁴¹⁵, Elizabeth A. Musgrove¹⁸⁷, Adnan M. Nagrial³⁵⁸, Felicity Newell^{340,341}, Katia Nones^{340,341}, Karin A. Oien^{411,430}, Marina Pajic³⁵⁸, Ann-Marie Patch^{340,341}, John V. Pearson^{340,341}, Mark Pinese⁴³¹, Michael C. Quinn^{340,341}, Alan J. Robertson²⁶⁹, Ilse Rooman³⁵⁸, Borislav C. Rusev⁴¹⁹, Jaswinder S. Samra^{415,421}, Maria Scardoni⁴¹⁸, Christopher J. Scarlett^{358,432}, Aldo Scarpa⁴¹⁹, Elisabetta Sereni⁴¹⁵, Katarzyna O. Sikora⁴¹⁹, Michele Simbolo⁴²³, Morgan L. Taschuk¹⁵, Christopher W. Toon³⁵⁸, Giampaolo Tortora^{229,230}, Caterina Vicentini⁴¹⁹, Nick M. Waddell³⁴¹, Nicola Waddell^{340,341}, Scott Wood^{340,341}, Jianmin Wu³⁵⁸, Qinying Xu^{340,341}, Nikolajs Zeps^{433,434}, Andrew V. Biankin^{187,358,366,367} & Sean M. Grimmond³⁶⁸

Tumour-specific providers (skin cancer) in Australia Lauri A. Aaltonen¹¹¹, Andreas Behren⁴³⁵, Hazel Burke⁴³⁶, Jonathan Cebon⁴³⁵, Rebecca A. Dagg⁴³⁷, Ricardo De Paoli-Iseppi⁴³⁸, Ken Dutton-Regester³⁴⁰, Matthew A. Field⁴³⁹, Anna Fitzgerald⁴⁴⁰, Sean M. Grimmond³⁶⁸, Peter Hersey⁴³⁶, Oliver Holmes^{340,341}, Valerie Jakrot⁴³⁶, Peter A. Johansson³⁴⁰, Hojabr Kakavand⁴³⁸, Stephen H. Kazakoff^{340,341}, Richard F. Kefford⁴⁴¹, Loretta M. S. Lau⁴⁴², Conrad R. Leonard^{340,341}, Georgina V. Long⁴⁴³, Felicity Newell^{340,341}, Katia Nones^{340,341}, Ann-Marie Patch^{340,341}, John V. Pearson^{340,341}, Hilda A. Pickett⁴⁴², Antonia L. Pritchard³⁴⁰, Gulietta M. Pupo⁴⁴⁴, Robyn P. M. Saw⁴⁴³, Sarah-Jane Schramm⁴⁴⁵, Mark Shackleton²⁷¹, Catherine A. Shang⁴⁴⁰, Ping Shang⁴⁴³, Andrew J.

Spillane⁴⁴³, Jonathan R. Stretch⁴⁴³, Varsha Tembe^{412,445}, John F. Thompson⁴⁴³, Ricardo E. Vilain⁴⁴⁶, Nick M. Waddell³⁴¹, Nicola Waddell^{340,341}, James S. Wilmott⁴⁴³, Scott Wood^{340,341}, Qinying Xu^{340,341}, Jean Y. Yang⁴⁴⁷, Nicholas K. Hayward^{340,436}, Graham J. Mann^{412,448,449} & Richard A. Scolyer^{413,443,446,450}

Tumour-specific providers (pancreatic cancer) in Canada John Bartlett^{451,452}, Prashant Bavi⁴⁵³, Ivan Borozan¹², Dianne E. Chadwick⁴⁵⁴, Michelle Chan-Seng-Yue⁴⁵³, Sean Cleary^{453,455}, Ashton A. Connor^{455,456}, Karolina Czajka²⁴¹, Robert E. Denroche⁴⁵³, Neesha C. Dhani⁴⁵⁷, Jenna Eagles²⁴¹, Vincent Ferretti^{15,86}, Steven Gallinger^{453,455,456}, Robert C. Grant^{453,456}, David Hedley⁴⁵⁷, Michael A. Hollingsworth⁴⁵⁸, Gun Ho Jang⁴⁵³, Jeremy Johns²⁴¹, Sangeetha Kalimuthu⁴⁵³, Sheng-Ben Liang⁴⁵⁹, Ilinca Lungu^{453,460}, Xuemei Luo¹², Faridah Mbabaali²⁴¹, Treasa A. McPherson⁴⁵⁶, Jessica K. Miller²⁴¹, Malcolm J. Moore⁴⁵⁷, Faiyaz Notta^{453,461}, Danielle Pasternack²⁴¹, Gloria M. Petersen⁴⁶², Michael H. A. Roehrl^{18,453,463,464,465}, Michelle Sam²⁴¹, Iris Selander⁴⁵⁶, Stefano Serra⁴¹¹, Sagedeh Shahabi⁴⁵⁹, Morgan L. Taschuk¹⁵, Sarah P. Thayer⁴⁵⁸, Lee E. Timms²⁴¹, Gavin W. Wilson^{12,453}, Julie M. Wilson⁴⁵³, Bradly G. Wouters⁴⁶⁶, Thomas J. Hudson^{240,241}, John D. McPherson^{241,453,467} & Lincoln D. Stein^{12,13}

Tumour-specific providers (prostate cancer) in Canada Timothy A. Beck^{15,468}, Vinayak Bhandari¹², Colin C. Collins¹⁴⁷, Shadrielle M. G. Espiritu¹², Neil E. Fleshner⁴⁶⁹, Natalie S. Fox¹², Michael Fraser¹², Syed Haider¹², Lawrence E. Heisler⁴⁷⁰, Vincent Huang¹², Emilie Lalonde¹², Julie Livingstone¹², John D. McPherson^{241,453,467}, Alice Meng⁴⁷¹, Veronica Y. Sabelnykova¹², Adriana Salcedo¹², Yu-Jia Shiah¹², Theodorus Van der Kwast⁴⁷², Takafumi N. Yamaguchi¹², Paul C. Boutros^{12,18,20,21} & Robert G. Bristow^{18,473,474,475,476}

Tumour-specific providers (gastric cancer) in China Shuai Ding⁴⁷⁷, Daiming Fan⁴⁷⁸, Yong Hou^{180,181}, Yi Huang^{158,257}, Lin Li¹⁸⁰, Siliang Li^{180,181}, Dongbing Liu^{180,181}, Xingmin Liu^{180,181}, Yongzhan Nie^{478,479}, Hong Su^{180,181}, Jian Wang¹⁸⁰, Kui Wu^{180,181}, Xiao Xiao¹⁵⁸, Rui Xing^{222,480}, Shanlin Yang⁴⁷⁷, Yingyan Yu⁴⁸¹, Xiuqing Zhang¹⁸⁰, Yong Zhou¹⁸⁰, Shida Zhu^{180,181}, Youyong Lu^{221,222,223} & Huanming Yang¹⁸⁰

Tumour-specific providers (renal cancer) in the EU and France Rosamonde E. Banks⁴⁸², Guillaume Bourque^{483,484}, Alvis Brazma⁷, Paul Brennan⁴⁸⁵, Louis Letourneau⁴⁸⁶, Yasser Riazalhosseini⁴⁸⁴, Ghislaine Scelo⁴⁸⁵, Naveen Vasudev^{482,487}, Juris Viksna⁴⁸⁸, Mark Lathrop⁴⁸⁴ & Jörg Tost⁴⁸⁹

Tumour-specific providers (breast cancer) in the EU & United Kingdom Sung-Min Ahn⁴⁹⁰, Ludmil B. Alexandrov^{1,101}, Samuel Aparicio⁴⁹¹, Laurent Arnould⁴⁹², M. R. Aure⁴⁹³, Shriram G. Bhosle¹, Ewan Birney⁷, Ake Borg⁴⁹⁴, Sandrine Boyault⁴⁹⁵, Arie B. Brinkman⁴⁹⁶, Jane E. Brock⁴⁹⁷, Annegien Broeks⁴⁹⁸, Adam P. Butler¹, Anne-Lise Borresen-Dale⁴⁹³, Carlos Caldas^{499,500}, Peter J. Campbell^{1,2}, Suet-Feung Chin^{499,500}, Helen Davies^{1,351,352}, Christine Desmedt^{501,502}, Luc Dirix⁵⁰³, Serge Dronov¹, Anna Ehinger⁵⁰⁴, Jorunn E. Eyfjord⁵⁰⁵, Aquila Fatima²⁰⁴, John A. Foekens⁵⁰⁶, P. Andrew Futreal⁵⁰⁷, Øystein Garred^{508,509}, Moritz Gerstung^{7,8}, Dilip D. Giri⁵¹⁰, Dominik Glodzik¹, Dorthe Grabau⁵¹¹, Holmfridur Hilmarsdottir⁵⁰⁵, Gerrit K. Hooijer⁵¹², Jocelyne Jacquemier⁵¹³, Se Jin Jang⁵¹⁴, Jon G. Jonasson⁵⁰⁵, Jos Jonkers⁵¹⁵, Hyung-Yong Kim⁵¹³, Tari A. King^{516,517}, Stian Knappskog^{1,518}, Gu Kong⁵¹³, Savitri Krishnamurthy⁵¹⁹, Sunil R. Lakhani⁵²⁰, Anita Langerød⁴⁹³, Denis Larsimont⁵²¹, Hee Jin Lee⁵¹⁴, Jeong-Yeon Lee⁵²², Ming Ta Michael Lee⁵⁰⁷, Yilong Li¹, Ole Christian Lingjærde⁵²³, Gaetan MacGrogan⁵²⁴, John W. M. Martens⁵⁰⁶, Sancha Martin^{1,362}, Iñigo Martincorena¹, Andrew Menzies¹, Sandro Morganella¹, Ville Mustonen^{347,348,349}, Serena Nik-Zainal^{1,351,352,353}, Sarah O'Meara¹, Iris Pauperté²¹⁴, Sarah Pinder⁵²⁵, Xavier Pivot⁵²⁶, Elena Provenzano⁵²⁷, Colin A. Purdie⁵²⁸, Keiran M. Raine¹, Manasa Ramakrishna¹, Kamna Ramakrishnan¹, Jorge Reis-Filho⁵¹⁰, Andrea L. Richardson²⁰⁴, Markus

Ringnér⁴⁹⁴, Javier Bartolomé Rodriguez⁴⁰, F. Germán Rodríguez-González²⁶¹, Gilles Romieu⁵²⁹, Roberto Salgado⁴¹¹, Torill Sauer⁵²³, Rebecca Shepherd¹, Anieta M. Sieuwerts⁵⁰⁶, Peter T. Simpson⁵²⁰, Marcel Smid⁵⁰⁶, Christos Sotiriou²³⁴, Paul N. Span⁵³⁰, Lucy Stebbings¹, Ólafur Andri Stefánsson⁵³¹, Alasdair Stenhouse⁵³², Henk G. Stunnenberg^{181,533}, Fred Sweep⁵³⁴, Benita Kiat Tee Tan⁵³⁵, Jon W. Teague¹, Gilles Thomas⁵³⁶, Alastair M. Thompson⁵³², Stefania Tommasi⁵³⁷, Isabelle Treilleux^{538,539}, Andrew Tutt²⁰⁴, Naoto T. Ueno³⁸⁷, Steven Van Laere⁵⁰³, Peter Van Loo^{91,92}, Gert G. Van den Eynden⁵⁰³, Peter Vermeulen⁵⁰³, Alain Viari⁴¹⁹, Anne Vincent-Salomon⁵³³, David C. Wedge^{1,65,66}, Bernice H. Wong⁵⁴⁰, Lucy Yates¹, Xueqing Zou¹, Carolien H. M. van Deurzen⁵⁴¹, Marc J. van de Vijver⁴¹¹, Laura van't Veer⁵⁴² & Michael R. Stratton¹

Tumour-specific providers (malignant lymphoma) in Germany Ole Ammerpohl^{543,544,546}, Sietse Aukema^{544,545,546}, Anke K. Bergmann⁵⁴⁷, Stephan H. Bernhart^{311,312,315}, Hans Binder^{311,312}, Arndt Borkhardt⁵⁴⁸, Christoph Borst⁵⁴⁹, Benedikt Brors^{127,150,323}, Birgit Burkhardt⁵⁵⁰, Alexander Claviez⁵⁵¹, Roland Eils^{28,30,143,144}, Maria Elisabeth Goebler⁵⁵², Andrea Haake⁵⁴³, Siegfried Haas⁵⁴⁹, Martin Hansmann⁵⁵³, Jessica I. Hoell⁵⁴⁸, Steve Hoffmann^{311,312,314,315}, Michael Hummel⁵⁵⁴, Daniel Hübschmann^{30,120,143,242,243}, Dennis Karsch⁵⁵⁵, Wolfram Klapper⁵⁴⁵, Kortine Kleinheinz^{28,30}, Michael Kneba⁵⁵⁵, Jan O. Korbel^{7,8}, Helene Kretzmer^{312,315}, Markus Kreuz⁵⁵⁶, Dieter Kube⁵⁵⁷, Ralf Küppers⁵⁵⁸, Chris Lawerenz¹⁴⁴, Dido Lenz⁵⁵⁴, Peter Lichter^{149,399}, Markus Loeffler⁵⁵⁶, Cristina López^{80,543}, Luisa Mantovani-Löffler⁵⁵⁹, Peter Möller⁵⁶⁰, German Ott⁵⁶¹, Bernhard Radlwimmer³⁹⁹, Julia Richter^{543,545}, Marius Rohde⁵⁶², Philip C. Rosenstiel⁵⁶³, Andreas Rosenwald⁵⁶⁴, Markus B. Schilhabel⁵⁶³, Matthias Schlesner^{28,31}, Stefan Schreiber⁵⁶⁵, Peter F. Stadler^{311,312,315}, Peter Staib⁵⁶⁶, Stephan Stilgenbauer⁵⁶⁷, Stephanie Sungalee⁸, Monika Szczepanowski⁵⁴⁵, Umut H. Toprak^{30,568}, Lorenz H. P. Trümper⁵⁵⁷, Rabea Wagener^{80,543}, Thorsten Zenz¹⁵⁰ & Reiner Siebert^{79,80}

Tumour-specific providers (paediatric brain cancer) in Germany Ivo Buchhalter^{28,29,30}, Juergen Eils^{143,144}, Roland Eils^{28,30,143,144}, Volker Hovestadt³⁹⁹, Barbara Hutter^{140,149,150}, David T. W. Jones^{331,332}, Natalie Jäger²⁸, Christof von Kalle¹²⁰, Marcel Kool^{246,331}, Jan O. Korbel^{7,8}, Andrey Korshunov²⁴⁶, Pablo Landgraf^{569,570}, Chris Lawerenz¹⁴⁴, Hans Lehrach⁵⁷¹, Paul A. Northcott⁵⁷², Stefan M. Pfister^{246,331,573}, Bernhard Radlwimmer³⁹⁹, Guido Reifenberger⁵⁷⁰, Matthias Schlesner^{28,31}, Hans-Jörg Warnatz⁵⁷¹, Joachim Weischenfeldt^{8,99,100}, Stephan Wolf⁵⁷⁴, Marie-Laure Yaspo⁵⁷¹, Marc Zapata³⁹⁹ & Peter Lichter^{149,399}

Tumour-specific providers (prostate cancer) in Germany Yassen Assenov⁵⁷⁵, Benedikt Brors^{127,150,323}, Juergen Eils^{143,144}, Roland Eils^{28,30,143,144}, Lars Feuerbach¹²⁷, Clarissa Gerhäuser³²⁰, Jan O. Korbel^{7,8}, Chris Lawerenz¹⁴⁴, Hans Lehrach⁵⁷¹, Sarah Minner⁵⁷⁶, Christoph Plass³²⁰, Thorsten Schlomm^{99,577}, Nikos Sidiropoulos¹⁰⁰, Ronald Simon⁵⁷⁸, Hans-Jörg Warnatz⁵⁷¹, Dieter Weichenhan³²⁰, Joachim Weischenfeldt^{8,99,100}, Marie-Laure Yaspo⁵⁷¹, Guido Sauter⁵⁷⁸ & Holger Sültmann^{150,579}

Tumour-specific providers (oral cancer) in India Nidhan K. Biswas⁵⁸⁰, Luca Landoni⁴¹⁵, Arindam Maitra⁵⁸⁰, Partha P. Majumder⁵⁸⁰ & Rajiv Sarin⁵⁸¹

Tumour-specific providers (pancreatic cancer) in Italy Davide Antonello⁴¹⁵, Stefano Barbi⁴²³, Claudio Bassi⁴¹⁵, Samantha Bersani⁴¹⁸, Giada Bonizzato⁴¹⁹, Cinzia Cantù⁴¹⁹, Ivana Cataldo^{418,419}, Sara Cingarlini²²⁹, Vincenzo Corbo^{419,423}, Maria Vittoria Davi⁴²⁴, Angelo P. Dei Tos⁵⁸², Matteo Fassan⁵⁸³, Sonia Grimaldi⁴¹⁹, Luca Landoni⁴¹⁵, Rita T. Lawlor⁴¹⁹, Claudio Luchini⁴¹⁸, Andrea Mafficini⁴¹⁹, Giuseppe Malleo⁴¹⁵, Giovanni Marchegiani⁴¹⁵, Michele Milella²²⁹, Marco Miotto⁴¹⁵, Salvatore Paiella⁴¹⁵, Antonio Pea⁴¹⁵, Paolo Pederzoli⁴¹⁵,

Borislav C. Rusev⁴¹⁹, Andrea Ruzzenente⁴¹⁵, Roberto Salvia⁴¹⁵, Maria Scardoni⁴¹⁸, Elisabetta Sereni⁴¹⁵, Michele Simbolo⁴²³, Nicola Sperandio⁴¹⁹, Giampaolo Tortora^{229,230}, Caterina Vicentini⁴¹⁹ & Aldo Scarpa⁴¹⁹

Tumour-specific providers (biliary tract cancer) in Japan Yasuhito Arai²²⁶, Natsuko Hama²²⁶, Nobuyoshi Hiraoka⁵⁸⁴, Fumie Hosoda^{226,226}, Mamoru Kato³⁶¹, Hiromi Nakamura²²⁶, Hidenori Ojima⁵⁸⁵, Takuji Okusaka⁵⁸⁶, Yasushi Totoki²²⁶, Tomoko Urushidate²²⁷ & Tatsuhiro Shibata^{226,227}

Tumour-specific providers (gastric cancer) in Japan Yasuhito Arai²²⁶, Masashi Fukayama⁵⁸⁷, Natsuko Hama²²⁶, Fumie Hosoda^{226,226}, Shunpei Ishikawa⁵⁸⁸, Hitoshi Katai⁵⁸⁹, Mamoru Kato³⁶¹, Hiroto Katoh⁵⁸⁸, Daisuke Komura⁵⁸⁸, Genta Nagae^{310,318}, Hiromi Nakamura²²⁶, Hirofumi Rokutan³⁶¹, Mihoko Saito-Adachi³⁶¹, Akihiro Suzuki^{310,590}, Hirokazu Taniguchi⁵⁹¹, Kenji Tatsuno³¹⁰, Yasushi Totoki²²⁶, Tetsuo Ushiku⁵⁸⁷, Shinichi Yachida^{226,592}, Shogo Yamamoto³¹⁰, Hiroyuki Aburatani³¹⁰ & Tatsuhiro Shibata^{226,227}

Tumour-specific providers (liver cancer) in Japan Hiroyuki Aburatani³¹⁰, Hiroshi Aikata⁵⁹³, Koji Arihiro⁵⁹³, Shun-ichi Ariizumi⁵⁹⁴, Keith A. Boroevich^{81,233}, Kazuaki Chayama⁵⁹³, Akihiro Fujimoto⁸¹, Masashi Fujita⁸¹, Mayuko Furuta⁸¹, Kunihito Gotoh⁵⁹⁵, Natsuko Hama²²⁶, Takanori Hasegawa³⁹, Shinya Hayami⁵⁹⁶, Shuto Hayashi³⁹, Satoshi Hirano⁵⁹⁷, Seiya Imoto³⁹, Mamoru Kato³⁶¹, Yoshiiku Kawakami⁵⁹³, Kazuhiro Maejima⁸¹, Satoru Miyano³⁹, Genta Nagae^{310,318}, Hiromi Nakamura²²⁶, Toru Nakamura⁵⁹⁷, Kaoru Nakano⁸¹, Hideki Ohdan⁵⁹³, Aya Sasaki-Oku⁸¹, Yuichi Shiraishi³⁹, Hiroko Tanaka³⁹, Yasushi Totoki²²⁶, Tatsuhiro Tsunoda^{233,294,295,296}, Masaki Ueno⁵⁹⁶, Rui Yamaguchi³⁹, Masakazu Yamamoto⁵⁹⁴, Hiroki Yamaue⁵⁹⁶, Hidewaki Nakagawa⁸¹ & Tatsuhiro Shibata^{226,227}

Tumour-specific providers (biliary tract cancer) in Singapore Su Pin Choo⁵⁹⁸, Ioana Cutcutache^{196,346}, Narong Khuntikeo^{415,599}, John R. McPherson^{196,346}, Choon Kiat Ong⁶⁰⁰, Chawalit Pairojkul⁴¹¹, Irinel Popescu⁶⁰¹, Steven G. Rozen^{196,197,346}, Patrick Tan^{190,195,196,197} & Bin Tean Teh^{195,196,197,198,199}

Tumour-specific providers (blood cancer) in South Korea Keun Soo Ahn⁶⁰², Hyung-Lae Kim⁵⁶, Youngil Koh^{336,337} & Sung-Soo Yoon³³⁷

Tumour-specific providers (chronic lymphocytic leukaemia) in Spain Marta Aymerich⁶⁰³, Josep L. Gelpí^{40,145}, Ivo G. Gut^{49,74}, Marta Gut^{49,74}, Armando Lopez-Guillermo⁶⁰⁴, Carlos López-Otín⁶⁰⁵, Xose S. Puente⁶⁰⁵, Romina Royo⁴⁰, David Torrents^{40,76} & Elias Campo^{606,607}

Tumour-specific providers (bone cancer) in the United Kingdom Fernanda Amary⁶⁰⁸, Daniel Baumhoer⁶⁰⁹, Sam Behjati¹, Bodil Bjerkehagen^{609,610}, P. A. Futreal⁵⁰⁷, Ola Myklebost⁵¹⁸, Nischalan Pillay⁶¹¹, Patrick Tarpey⁶¹², Roberto Tirabosco⁶¹³, Olga Zaikova⁶¹⁴, Peter J. Campbell^{1,2} & Adrienne M. Flanagan⁶¹⁵

Tumour-specific providers (chronic myeloid disorders) in the United Kingdom Jacqueline Boultwood⁶¹⁶, David T. Bowen¹, Adam P. Butler¹, Mario Cazzola⁶¹⁷, Carlo Gambacorti-Passerini²⁷⁰, Anthony R. Green³²⁹, Eva Hellstrom-Lindberg⁶¹⁸, Luca Malcovati⁶¹⁷, Sancha Martin^{1,362}, Jyoti Nangalia⁶¹⁹, Elli Papaemmanuil¹, Paresh Vyas^{340,620} & Peter J. Campbell^{1,2}

Tumour-specific providers (oesophageal cancer) in the United Kingdom Yeng Ang⁶²¹, Hugh Barr⁶²², Duncan Beardsmore⁶²³, Matthew Eldridge³²⁸, James Gossage⁶²⁴, Nicola Grehan³⁵², George B. Hanna⁶²⁵, Stephen J. Hayes^{626,627}, Ted R. Hupp⁶²⁸, David Khoo⁶²⁹, Jesper Lagergren^{618,630}, Laurence B. Lovat¹⁸⁹, Shona MacRae¹³⁷, Maria O'Donovan³⁵², J. Robert O'Neill⁶³¹, Simon L. Parsons⁶³², Shaun R. Preston⁶³³, Sonia Puig⁶³⁴, Tom

Roques⁶³⁵, Grant Sanders²⁴, Sharmila Sothi⁶³⁶, Simon Tavaré³²⁸, Olga Tucker⁶³⁷, Richard Turkington⁶³⁸, Timothy J. Underwood⁶³⁹, Ian Welch⁶⁴⁰ & Rebecca C. Fitzgerald³⁵²

Tumour-specific providers (prostate cancer) in the United Kingdom Daniel M. Berney⁶⁴¹, Johann S. De Bono³⁹⁶, G. Steven Bova¹²⁶, Daniel S. Brewer^{394,395}, Adam P. Butler¹, Declan Cahill⁶⁴², Niedzica Camacho³⁹⁶, Nening M. Dennis⁶⁴², Tim Dudderidge^{642,643}, Sandra E. Edwards³⁹⁶, Cyril Fisher⁶⁴², Christopher S. Foster^{644,645}, Mohammed Ghori¹, Plevender Gill⁶²⁰, Vincent J. Gnanapragasam^{379,646}, Gunes Gundem²⁷⁸, Freddie C. Hamdy⁶⁴⁷, Steve Hawkins³²⁸, Steven Hazell⁶⁴², William Howat³⁷⁹, William B. Isaacs⁶⁴⁸, Katalin Karaszsi⁶²⁰, Jonathan D. Kay¹⁸⁹, Vincent Khoo⁶⁴², Zsofia Kote-Jarai³⁹⁶, Barbara Kremeyer¹, Pardeep Kumar⁶⁴², Adam Lambert⁶²⁰, Daniel A. Leongamornlert^{1,396}, Naomi Livni⁶⁴², Yong-Jie Lu^{641,649}, Hayley J. Luxton¹⁸⁹, Andy G. Lynch^{328,329,339}, Luke Marsden⁶²⁰, Charlie E. Massie³²⁸, Lucy Matthews³⁹⁶, Erik Mayer^{642,650}, Ultan McDermott¹, Sue Merson³⁹⁶, Thomas J. Mitchell^{1,329,379}, David E. Neal^{328,379}, Anthony Ng⁶⁵¹, David Nicol⁶⁴², Christopher Ogden⁶⁴², Edward W. Rowe⁶⁴², Nimish C. Shah³⁷⁹, Jon W. Teague¹, Sarah Thomas⁶⁴², Alan Thompson⁶⁴², Peter Van Loo^{91,92}, Clare Verrill^{620,652}, Tapio Visakorpi¹²⁶, Anne Y. Warren^{379,653}, David C. Wedge^{1,65,66}, Hayley C. Whitaker¹⁸⁹, Jorge Zamora^{1,42,43,44}, Hongwei Zhang⁶⁴⁹, Nicholas van As⁶⁴², Colin S. Cooper^{395,396,397} & Rosalind A. Eeles^{396,642}

Tumour-specific providers (TCGA) in the United States Adam Abeshouse²⁷⁸, Nishant Agrawal¹⁶³, Rehan Akbani^{352,654}, Hikmat Al-Ahmadie²⁷⁸, Monique Albert⁴⁵², Kenneth Aldape^{400,655}, Adrian Ally⁶⁵⁶, Yeng Ang⁶²¹, Elizabeth L. Appelbaum^{27,189}, Joshua Armenia⁶⁵⁷, Sylvia Asa^{632,658}, J. Todd Auman⁶⁵⁹, Matthew H. Bailey^{26,27}, Miruna Balasundaram⁶⁵⁶, Saianand Balu²⁴, Jill Barnholtz-Sloan^{660,661}, Hugh Barr⁶²², John Bartlett^{451,452}, Oliver F. Bath^{662,663}, Stephen B. Baylin^{123,643}, Duncan Beardsmore⁶²³, Christopher Benz⁶⁶⁴, Andrew Berchuck⁶⁶⁵, Benjamin P. Berman^{313,321,322}, Rameen Beroukhim^{3,6,168}, Mario Berrios⁶⁶⁶, Darell Bigner⁶⁶⁷, Michael Birrer¹⁹, Tom Bodenheimer²⁴, Lori Boice⁶³⁴, Moiz S. Bootwalla⁶⁶⁶, Marcus Bosenberg⁶⁶⁸, Reanne Bowlby⁶⁵⁶, Jeffrey Boyd⁶⁶⁹, Russell R. Broaddus⁴⁰⁰, Malcolm Brock⁶⁷⁰, Denise Brooks⁶⁵⁶, Susan Bullman^{3,168}, Samantha J. Caesar-Johnson²³¹, Thomas E. Carey⁶⁷¹, Rebecca Carlsen⁶⁵⁶, Robert Cerfolio⁶⁷², Vishal S. Chandan⁶⁷³, Hsiao-Wei Chen^{621,657}, Andrew D. Cherniack^{3,3,157,168}, Jeremy Chien⁶⁷⁴, Juok Cho³, Eric Chuah⁶⁵⁶, Carrie Cibulskis³, Kristian Cibulskis³, Leslie Cope⁶⁷⁵, Matthew G. Cordes^{27,635}, Kyle Covington³⁴, Erin Curley⁶⁷⁶, Bogdan Czerniak^{400,629}, Ludmila Danilova⁶⁷⁵, Ian J. Davis⁶⁷⁷, Timothy Defreitas³, John A. Demchok²³¹, Noreen Dhalla⁶⁵⁶, Rajiv Dhir⁶⁷⁸, Li Ding^{26,27,35}, HarshaVardhan Doddapaneni³⁴, Adel El-Naggar^{400,629}, Ina Felau²³¹, Martin L. Ferguson⁶⁷⁹, Gaetano Finocchiaro⁶⁸⁰, Kwun M. Fong⁶⁸¹, Scott Frazer³, William Friedman⁶⁸², Catrina C. Fronick^{27,635}, Lucinda A. Fulton²⁷, Robert S. Fulton^{26,27,35}, Stacey B. Gabriel³, Jianjiang Gao⁶⁵⁷, Nils Gehlenborg^{3,683}, Jeffrey E. Gershenwald^{684,685}, Gad Getz^{3,4,5,6}, Ronald Ghossein⁵¹⁰, Nasra H. Giama⁶⁸⁶, Richard A. Gibbs³⁴, Carmen Gomez⁶⁸⁷, James Gossage⁶²⁴, Ramaswamy Govindan²⁶, Nicola Grehan³⁵², George B. Hanna⁶²⁵, D. Neil Hayes^{24,688,689}, Stephen J. Hayes^{626,627}, Apurva M. Hegde^{137,138}, David I. Heiman³, Zachary Heins²⁷⁸, Austin J. Hepperla²⁴, Katherine A. Hoadley^{23,24}, Andrea Holbrook⁶⁶⁶, Robert A. Holt⁶⁵⁶, Alan P. Hoyle²⁴, Ralph H. Hruban^{675,675}, Jianhong Hu³⁴, Mei Huang⁶³⁴, David Huntsman⁶⁹⁰, Ted R. Hupp⁶²⁸, Jason Huse²⁷⁸, Christine A. Iacobuzio-Donahue⁵¹⁰, Michael Ittmann^{691,692}, Joy C. Jayaseelan³⁴, Stuart R. Jefferys²⁴, Corbin D. Jones⁶⁹³, Steven J. M. Jones⁶⁹⁴, Hartmut Juhl⁶⁹⁵, Koo Jeong Kang⁶⁹⁶, Beth Karlan⁶⁹⁷, Katayoon Kasaian⁶⁹⁴, Electron Kebebew^{698,699}, David Khoo⁶²⁹, Hark Kyun Kim⁷⁰⁰, Jaegil Kim³, Tari A. King^{516,517}, Viktoriya Korchina³⁴, Ritika Kundra^{621,657}, Jesper Lagergren^{618,630}, Phillip H. Lai⁶⁶⁶, Peter W. Laird³¹⁶, Eric Lander³, Michael S. Lawrence^{3,19,233}, Alexander J. Lazar²², Xuan Le⁷⁰¹, Darlene Lee⁶⁵⁶, Douglas A. Levine^{278,702},

Lora Lewis³⁴, Tim Ley⁷⁰³, Haiyan Irene Li⁶⁵⁶, Pei Lin³, W. M. Linehan⁷⁰⁴, Eric Minwei Liu^{71,73,278}, Fei Fei Liu³⁸⁰, Laurence B. Lovat¹⁸⁹, Yiling Lu¹³⁸, Lisa Lype⁷⁰⁵, Yussanne Ma⁶⁵⁶, Shona MacRae¹³⁷, Dennis T. Maglinte^{666,706}, Elaine R. Mardis^{27,669,707}, Jeffrey Marks^{415,708}, Marco A. Marra⁶⁵⁶, Thomas J. Matthew³⁷, Michael Mayo⁶⁵⁶, Karen McCune⁷⁰⁹, Michael D. McLellan^{26,27,35}, Samuel R. Meier³, Shaowu Meng²⁴, Matthew Meyerson^{3,6,157}, Piotr A. Mieczkowski²³, Tom Mikkelsen⁷¹⁰, Christopher A. Miller²⁷, Gordon B. Mills⁷¹¹, Richard A. Moore⁶⁵⁶, Carl Morrison^{411,712}, Lisle E. Mose²⁴, Catherine D. Moser⁶⁸⁶, Andrew J. Mungall⁶⁵⁶, Karen Mungall⁶⁵⁶, David Mutch⁷¹³, Donna M. Muzny⁷¹⁴, Jerome Myers⁷¹⁵, Yulia Newton³⁷, Michael S. Noble³, Peter O'Donnell⁷¹⁶, Brian Patrick O'Neill⁷¹⁷, Angelica Ochoa²⁷⁸, Akinyemi I. Ojesina^{191,192,193}, Joong-Won Park⁷¹⁸, Joel S. Parker⁷¹⁹, Simon L. Parsons⁶³², Harvey Pass⁷²⁰, Alessandro Pastore¹¹², Chandra Sekhar Pedamallu^{3,6,168}, Nathan A. Pennell⁷²¹, Charles M. Perou⁷²², Gloria M. Petersen⁴⁶², Nicholas Petrelli⁷²³, Olga Potapova⁷²⁴, Shaun R. Preston⁶³³, Sonia Puig⁶³⁴, Janet S. Rader⁷²⁵, Suresh Ramalingam⁷²⁶, W. Kimryn Rathmell⁷²⁷, Victor Reuter⁵¹⁰, Sheila M. Reynolds⁷⁰⁵, Matthew Ringel⁷²⁸, Jeffrey Roach⁷²⁹, Lewis R. Roberts⁶⁸⁶, A. Gordon Robertson⁶⁵⁶, Tom Roques⁶³⁵, Mark A. Rubin^{274,287,288,289,290}, Sara Sadeghi⁶⁵⁶, Gordon Saksena³, Charles Saller⁷³⁰, Francisco Sanchez-Vega^{621,657}, Chris Sander^{112,157,291,292}, Grant Sanders²⁴, Dirk Schadendorf^{149,731}, Jacqueline E. Schein⁶⁵⁶, Heather K. Schmidt²⁷, Nikolaus Schultz⁶⁵⁷, Steven E. Schumacher^{3,204}, Richard A. Scolyer^{413,443,446,450}, Raja Seethala⁷³², Yasin Senbabaoglu¹¹², Troy Shelton⁶⁷⁶, Yan Shi²⁴, Julianne Shih^{3,168}, Ilya Shmulevich⁷⁰⁵, Craig Shriver⁷³³, Sabina Signoretti^{168,263,734}, Janae V. Simons²⁴, Samuel Singer^{415,735}, Payal Sipahimalani⁶⁵⁶, Tara J. Skelly²³, Karen Smith-McCune⁷⁰⁹, Nicholas D. Socci¹¹², Heidi J. Sofia²¹⁷, Matthew G. Soloway⁷¹⁹, Anil K. Sood⁷³⁶, Sharmila Sothi⁶³⁶, Angela Tam⁶⁵⁶, Donghui Tan²³, Roy Tarnuzzer²³¹, Nina Thiessen⁶⁵⁶, R. Houston Thompson⁷³⁷, Leigh B. Thorne⁶³⁴, Ming Tsao^{632,658}, Olga Tucker⁶³⁷, Richard Turkington⁶³⁸, Christopher Umbricht^{324,623,738}, Timothy J. Underwood⁶³⁹, David J. Van Den Berg⁶⁶⁶, Erwin G. Van Meir⁷³⁹, Umadevi Veluvolu²³, Douglas Voet³, Jiayin Wang^{27,58,158}, Linghua Wang³⁴, Zhining Wang²³¹, Paul Weinberger⁷⁴⁰, John N. Weinstein^{137,138}, Daniel J. Weisenberger⁶⁶⁶, Ian Welch⁶⁴⁰, David A. Wheeler^{33,34}, Dennis Wigle⁷⁴¹, Matthew D. Wilkerson²³, Richard K. Wilson^{27,742}, Boris Winterhoff⁷⁴³, Maciej Wiznerowicz^{744,745}, Tina Wong^{27,656}, Winghing Wong⁷⁴⁶, Liu Xi³⁴, Liming Yang²³¹, Christina Yau⁶⁶⁴, Venkata D. Yellapantula^{67,68}, Hailei Zhang³, Hongxin Zhang⁶⁵⁷, Jiashan Zhang²³¹, Carolyn M. Hutter²¹⁷ & Jean C. Zenklusen²³¹

¹Wellcome Sanger Institute, Hinxton, UK.

²Department of Haematology, University of Cambridge, Cambridge, UK.

³Broad Institute of MIT and Harvard, Cambridge, MA, USA.

⁴Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.

⁵Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.

⁶Harvard Medical School, Boston, MA, USA.

⁷European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, UK.

⁸European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany.

⁹Biomolecular Engineering Department, University of California Santa Cruz, Santa Cruz, CA, USA.

¹⁰Adaptive Oncology Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

¹¹International Cancer Genome Consortium (ICGC)/ICGC Accelerating Research in Genomic Oncology (ICGC-ARGO) Secretariat, Toronto, Ontario, Canada.

¹²Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

¹³Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

¹⁴Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.

¹⁵Genome Informatics Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

¹⁶Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada.

¹⁷Genome Informatics, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

¹⁸Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

¹⁹Massachusetts General Hospital, Boston, MA, USA.

²⁰Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.

²¹University of California Los Angeles, Los Angeles, CA, USA.

²²Department of Pathology, Department of Genomic Medicine and Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

²³Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

²⁴Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

²⁵The Hospital for Sick Children, Toronto, Ontario, Canada.

²⁶Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA.

²⁷The McDonnell Genome Institute, Washington University, St Louis, MO, USA.

²⁸Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

²⁹Heidelberg Center for Personalized Oncology (DKFZ-HIPO), German Cancer Research Center, Heidelberg, Germany.

³⁰Institute of Pharmacy and Molecular Biotechnology, and BioQuant, Heidelberg University, Heidelberg, Germany.

³¹Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

³²Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

³³Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.

³⁴Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.

³⁵Department of Genetics and Department of Medicine, Washington University in St Louis, St Louis, MO, USA.

³⁶Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.

³⁷University of California Santa Cruz, Santa Cruz, CA, USA.

³⁸Computational Biology Program, Oregon Health & Science University, Portland, OR, USA.

³⁹The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

⁴⁰Barcelona Supercomputing Center (BSC), Barcelona, Spain.

⁴¹Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

⁴²Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

⁴³Department of Zoology, Genetics and Physical Anthropology, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

⁴⁴The Biomedical Research Centre (CINBIO), Universidade de Vigo, Vigo, Spain.

⁴⁵Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.

⁴⁶Annai Systems, Carlsbad, CA, USA.

⁴⁷Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

⁴⁸Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

⁴⁹Universitat Pompeu Fabra (UPF), Barcelona, Spain.

⁵⁰Department of Computational Biology, University of Lausanne, Lausanne, Switzerland.

⁵¹Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.

⁵²Swiss Institute of Bioinformatics, University of Geneva, Geneva, Switzerland.

⁵³Department of Ophthalmology, Ocular Genomics Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.

⁵⁴Department of Experimental and Health Sciences, Institute of Evolutionary Biology (UPF-CSIC), Universitat Pompeu Fabra (UPF), Barcelona, Spain.

⁵⁵Department of Veterinary Medicine, Transmissible Cancer Group, University of Cambridge, Cambridge, UK.

⁵⁶Department of Biochemistry, College of Medicine, Ewha Womans University, Seoul, South Korea.

⁵⁷Division of Oncology, Washington University School of Medicine, St Louis, MO, USA.

⁵⁸School of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an, China.

⁵⁹The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.

⁶⁰Independent Consultant, Wellesley, MA, USA.

⁶¹Icahn School of Medicine at Mount Sinai, New York, NY, USA.

⁶²Biobyte Solutions, Heidelberg, Germany.

⁶³Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA.

⁶⁴Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA.

⁶⁵Big Data Institute, Li Ka Shing Centre, University of Oxford, Oxford, UK.

⁶⁶Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.

⁶⁷Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

⁶⁸The McDonnell Genome Institute at Washington University School of Medicine, and Department of Genetics and Department of Medicine, Siteman Cancer Center, Washington University in St Louis, St Louis, MO, USA.

⁶⁹Department of Computer Science, Yale University, New Haven, CT, USA.

⁷⁰Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

⁷¹Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.

⁷²Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.

⁷³Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.

⁷⁴CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

⁷⁵Department of Experimental and Health Sciences, Institute of Evolutionary Biology (UPF-CSIC), Universitat Pompeu Fabra (UPF), Barcelona, Spain.

⁷⁶Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

⁷⁷Institut Català de Paleontologia Miquel Crusafont, Universitat Autònoma de Barcelona, Barcelona, Spain.

⁷⁸Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.

⁷⁹Human Genetics, University of Kiel, Kiel, Germany.

⁸⁰Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.

⁸¹RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

⁸²Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.

⁸³Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.

⁸⁴Quantitative Genomics Laboratories (qGenomics), Barcelona, Spain.

⁸⁵Sage Bionetworks, Seattle, WA, USA.

⁸⁶Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, Quebec, Canada.

⁸⁷Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.

⁸⁸National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore, India.

⁸⁹Research Program on Biomedical Informatics, Universitat Pompeu Fabra (UPF), Barcelona, Spain.

⁹⁰Broad Institute of Harvard and MIT, Cambridge, MA, USA.

⁹¹The Francis Crick Institute, London, UK.

⁹²University of Leuven, Leuven, Belgium.

⁹³Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Cambridge, UK.

⁹⁴Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.

⁹⁵Ludwig Center at Harvard Medical School, Boston, MA, USA.

⁹⁶Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

⁹⁷Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences (NIEHS), Durham, NC, USA.

⁹⁸Integrative Bioinformatics Support Group, National Institute of Environmental Health Sciences (NIEHS), Durham, NC, USA.

⁹⁹Department of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany.

¹⁰⁰Finsen Laboratory and Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.

¹⁰¹Department of Bioengineering and Department of Cellular and Molecular Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.

¹⁰²Department of Genetics, Microbiology and Statistics, University of Barcelona, IRSJD, IBUB, Barcelona, Spain.

¹⁰³CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

¹⁰⁴Research Group on Statistics, Econometrics and Health (GRECS), UdG, Barcelona, Spain.

¹⁰⁵Oxford Nanopore Technologies, New York, NY, USA.

¹⁰⁶Applications Department, Oxford Nanopore Technologies, Oxford, UK.

¹⁰⁷School of Molecular Biosciences and Center for Reproductive Biology, Washington State University, Pullman, WA, USA.

¹⁰⁸Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

¹⁰⁹Department of Medical and Clinical Genetics, Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland.

¹¹⁰Integrated Graduate Program in Physical and Engineering Biology, Yale University, New Haven, CT, USA.

¹¹¹Applied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.

¹¹²Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

¹¹³Department of Biology, ETH Zurich, Zurich, Switzerland.

¹¹⁴Department of Computer Science, ETH Zurich, Zurich, Switzerland.

¹¹⁵SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.

¹¹⁶University Hospital Zurich, Zurich, Switzerland.

¹¹⁷Weill Cornell Medical College, New York, NY, USA.

¹¹⁸Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine, Berlin, Germany.

¹¹⁹German Cancer Consortium (DKTK), Partner site Berlin, Berlin, Germany.

¹²⁰German Cancer Research Center (DKFZ), Heidelberg, Germany.

¹²¹Bakar Computational Health Sciences Institute and Department of Pediatrics, University of California, San Francisco, CA, USA.

¹²²Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.

¹²³Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.

¹²⁴Division of Computational Genomics and Systems Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

¹²⁵Department of Medicine and Moores Cancer Center, Division of Biomedical Informatics, UC San Diego School of Medicine, San Diego, CA, USA.

¹²⁶Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.

¹²⁷Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

¹²⁸Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

¹²⁹Centre for Law and Genetics, University of Tasmania, Hobart, Tasmania, Australia.

¹³⁰Centre of Genomics and Policy, McGill University and Génome Québec Innovation Centre, Montreal, Quebec, Canada.

¹³¹Heidelberg Academy of Sciences and Humanities, Heidelberg, Germany.

¹³²UC Santa Cruz Genomics Institute, University of California Santa Cruz, Santa Cruz, CA, USA.

¹³³CIBIO/InBIO, Research Center in Biodiversity and Genetic Resources, Universidade do Porto, Vairão, Portugal.

¹³⁴Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

¹³⁵Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

¹³⁶Howard Hughes Medical Institute, University of California Santa Cruz, Santa Cruz, CA, USA.

¹³⁷Cancer Unit, MRC University of Cambridge, Cambridge, UK.

¹³⁸Department of Bioinformatics and Computational Biology and Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

¹³⁹Center for Digital Health, Berlin Institute of Health (BIH) and Charité–Universitätsmedizin Berlin, Berlin, Germany.

¹⁴⁰Heidelberg Center for Personalized Oncology (DKFZ-HIPO), German Cancer Research Center (DKFZ), Heidelberg, Germany.

¹⁴¹Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

¹⁴²Department of Genetics and Informatics Institute, University of Alabama at Birmingham, Birmingham, AL, USA.

¹⁴³Heidelberg University, Heidelberg, Germany.

¹⁴⁴New BIH Digital Health Center, Berlin Institute of Health (BIH) and Charité–Universitätsmedizin Berlin, Berlin, Germany.

¹⁴⁵Department of Biochemistry and Molecular Biomedicine, University of Barcelona, Barcelona, Spain.

¹⁴⁶Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

¹⁴⁷Vancouver Prostate Centre, Vancouver, British Columbia, Canada.

¹⁴⁸Division of Life Science and Applied Genomics Center, Hong Kong University of Science and Technology, Hong Kong, China.

¹⁴⁹German Cancer Consortium (DKTK), Heidelberg, Germany.

¹⁵⁰National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.

¹⁵¹Genome Integration Data Center, Syntekabio, Daejon, South Korea.

¹⁵²Massachusetts General Hospital Center for Cancer Research, Charlestown, MA, USA.

¹⁵³Department of Molecular Medicine (MOMA), Aarhus University Hospital, Aarhus, Denmark.

¹⁵⁴Bioinformatics Research Centre (BiRC), Aarhus University, Aarhus, Denmark.

¹⁵⁵Indiana University, Bloomington, IN, USA.

¹⁵⁶Simon Fraser University, Burnaby, British Columbia, Canada.

¹⁵⁷Dana-Farber Cancer Institute, Boston, MA, USA.

¹⁵⁸School of Computer Science and Technology, Xi'an Jiaotong University, Xi'an, China.

¹⁵⁹Department of Genetics, Washington University School of Medicine, St Louis, MO, USA.

¹⁶⁰Department of Mathematics, Washington University in St Louis, St Louis, MO, USA.

¹⁶¹Department of Biological Oceanography, Leibniz Institute of Baltic Sea Research, Rostock, Germany.

¹⁶²Seven Bridges Genomics, Charlestown, MA, USA.

¹⁶³University of Chicago, Chicago, IL, USA.

¹⁶⁴Department of Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, South Korea.

¹⁶⁵Samsung Genome Institute, Seoul, South Korea.

¹⁶⁶New York Genome Center, New York, NY, USA.

¹⁶⁷Weill Cornell Medicine, New York, NY, USA.

¹⁶⁸Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

¹⁶⁹Rigshospitalet, Copenhagen, Denmark.

¹⁷⁰Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.

¹⁷¹The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.

¹⁷²Vector Institute, Toronto, Ontario, Canada.

¹⁷³Department of Medical Genetics, College of Medicine, Hallym University, Chuncheon, South Korea.

¹⁷⁴Department of Biology, ETH Zurich, Zurich, Switzerland.

¹⁷⁵University Hospital Zurich, Zurich, Switzerland.

¹⁷⁶Peking University, Beijing, China.

¹⁷⁷School of Life Sciences, Peking University, Beijing, China.

¹⁷⁸Computational and Systems Biology, Genome Institute of Singapore, Singapore, Singapore.

¹⁷⁹School of Computing, National University of Singapore, Singapore, Singapore.

¹⁸⁰BGI-Shenzhen, Shenzhen, China.

¹⁸¹China National GeneBank-Shenzhen, Shenzhen, China.

¹⁸²Computational & Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

¹⁸³Korea University, Seoul, South Korea.

¹⁸⁴Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

¹⁸⁵Quantitative & Computational Biosciences Graduate Program, Baylor College of Medicine, Houston, TX, USA.

¹⁸⁶The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

¹⁸⁷Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, UK.

¹⁸⁸The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

¹⁸⁹University College London, London, UK.

¹⁹⁰Genome Institute of Singapore, Singapore, Singapore.

¹⁹¹Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.

¹⁹²HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.

¹⁹³O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.

¹⁹⁴Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.

¹⁹⁵Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

¹⁹⁶Programme in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.

¹⁹⁷SingHealth, Duke-NUS Institute of Precision Medicine, National Heart Centre Singapore, Singapore, Singapore.

¹⁹⁸Institute of Molecular and Cell Biology, Singapore, Singapore.

¹⁹⁹Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore, Singapore.

²⁰⁰Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

²⁰¹National Cancer Centre Singapore, Singapore, Singapore.

²⁰²BIOPIC, ICG and College of Life Sciences, Peking University, Beijing, China.

²⁰³Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain.

²⁰⁴Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.

²⁰⁵Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

²⁰⁶Department of Mathematics, Aarhus University, Aarhus, Denmark.

²⁰⁷Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain.

²⁰⁸King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

²⁰⁹DLR Project Management Agency, Bonn, Germany.

²¹⁰Genome Canada, Ottawa, Ontario, Canada.

²¹¹Instituto Carlos Slim de la Salud, Mexico City, Mexico.

²¹²Federal Ministry of Education and Research, Berlin, Germany.

²¹³Institut Gustave Roussy, Villejuif, France.

²¹⁴Institut National du Cancer (INCA), Boulogne-Billancourt, France.

²¹⁵The Wellcome Trust, London, UK.

²¹⁶Prostate Cancer Canada, Toronto, Ontario, Canada.

²¹⁷National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

²¹⁸Department of Biotechnology, Ministry of Science & Technology, Government of India, New Delhi, Delhi, India.

²¹⁹Science Writer, Garrett Park, MD, USA.

²²⁰Cancer Research UK, London, UK.

²²¹Chinese Cancer Genome Consortium, Shenzhen, China.

²²²Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.

²²³Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.

²²⁴National Cancer Center, Tokyo, Japan.

²²⁵German Cancer Aid, Bonn, Germany.

²²⁶Division of Cancer Genomics, National Cancer Center Research Institute, National Cancer Center, Tokyo, Japan.

²²⁷Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.

²²⁸Japan Agency for Medical Research and Development, Chiyoda-ku, Tokyo, Japan.

²²⁹Medical Oncology, University and Hospital Trust of Verona, Verona, Italy.

²³⁰University of Verona, Verona, Italy.

²³¹National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

²³²CAPHRI Research School, Maastricht University, Maastricht, The Netherlands.

²³³Laboratory for Medical Science Mathematics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

²³⁴University of California San Diego, San Diego, CA, USA.

²³⁵PDXen Biosystems, Seoul, South Korea.

²³⁶Electronics and Telecommunications Research Institute, Daejeon, South Korea.

²³⁷Children's Hospital of Philadelphia, Philadelphia, PA, USA.

²³⁸University of Melbourne Centre for Cancer Research, Melbourne, Victoria, Australia.

²³⁹Syntekabio, Daejon, South Korea.

²⁴⁰AbbVie, North Chicago, IL, USA.

²⁴¹Genomics Research Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

²⁴²Department of Pediatric Immunology, Hematology and Oncology, University Hospital, Heidelberg, Germany.

²⁴³Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.

²⁴⁴Seven Bridges, Charlestown, MA, USA.

²⁴⁵Health Sciences Department of Biomedical Informatics, University of California San Diego, La Jolla, CA, USA.

²⁴⁶Functional and Structural Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

²⁴⁷Leidos Biomedical Research, McLean, VA, USA.

²⁴⁸CSRA Incorporated, Fairfax, VA, USA.

²⁴⁹Department of Internal Medicine, Stanford University, Stanford, CA, USA.

²⁵⁰Clinical Bioinformatics, Swiss Institute of Bioinformatics, Geneva, Switzerland.

²⁵¹Institute for Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

²⁵²Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.

²⁵³MIT Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.

²⁵⁴Institute of Molecular Life Sciences and Swiss Institute of Bioinformatics, University of Zurich, Zurich, Switzerland.

²⁵⁵Office of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

²⁵⁶Computer Network Information Center, Chinese Academy of Sciences, Beijing, China.

²⁵⁷Geneplus-Shenzhen, Shenzhen, China.

²⁵⁸Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.

²⁵⁹Department of Pediatrics, Harvard Medical School, Boston, MA, USA.

²⁶⁰Technical University of Denmark, Lyngby, Denmark.

²⁶¹University of Copenhagen, Copenhagen, Denmark.

²⁶²Department for BioMedical Research, University of Bern, Bern, Switzerland.

²⁶³Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.

²⁶⁴Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.

²⁶⁵Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

²⁶⁶Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

²⁶⁷Korea Advanced Institute of Science and Technology, Daejeon, South Korea.

²⁶⁸Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.

²⁶⁹Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.

²⁷⁰University of Milano Bicocca, Monza, Italy.

²⁷¹Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.

²⁷²Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center, Houston, TX, USA.

²⁷³Health Data Science Unit, University Clinics, Heidelberg, Germany.

²⁷⁴Department for Biomedical Research, University of Bern, Bern, Switzerland.

²⁷⁵Research Core Center, National Cancer Centre Korea, Goyang-si, South Korea.

²⁷⁶Institute of Computer Science, Polish Academy of Sciences, Warsaw, Poland.

²⁷⁷Harvard University, Cambridge, MA, USA.

²⁷⁸Memorial Sloan Kettering Cancer Center, New York, NY, USA.

²⁷⁹Department of Information Technology, Ghent University, Ghent, Belgium.

²⁸⁰Department of Plant Biotechnology and Bioinformatics, Ghent University, Ghent, Belgium.

²⁸¹Yale School of Medicine, Yale University, New Haven, CT, USA.

²⁸²Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

²⁸³Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, South Korea.

²⁸⁴Cheonan Industry-Academic Collaboration Foundation, Sangmyung University, Cheonan, South Korea.

²⁸⁵Spanish National Cancer Research Centre, Madrid, Spain.

²⁸⁶Department of Computer Science, Princeton University, Princeton, NJ, USA.

²⁸⁷Bern Center for Precision Medicine, University Hospital of Bern, University of Bern, Bern, Switzerland.

²⁸⁸Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, USA.

²⁸⁹Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

²⁹⁰Pathology and Laboratory, Weill Cornell Medical College, New York, NY, USA.

²⁹¹cBio Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

²⁹²Department of Cell Biology, Harvard Medical School, Boston, MA, USA.

²⁹³cBio Center, Dana-Farber Cancer Institute, Boston, MA, USA.

²⁹⁴CREST, Japan Science and Technology Agency, Tokyo, Japan.

²⁹⁵Department of Medical Science Mathematics, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.

²⁹⁶Laboratory for Medical Science Mathematics, Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

²⁹⁷Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

²⁹⁸Department of Gene Technology, Tallinn University of Technology, Tallinn, Estonia.

²⁹⁹Genetics & Genome Biology Program, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.

³⁰⁰Department of Information Technology, Ghent University, Interuniversitair Micro-Electronica Centrum (IMEC), Ghent, Belgium.

³⁰¹Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

³⁰²Oregon Health & Sciences University, Portland, OR, USA.

³⁰³Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

³⁰⁴The University of Texas Health Science Center at Houston, Houston, TX, USA.

³⁰⁵Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA.

³⁰⁶The Ohio State University Comprehensive Cancer Center (OSUCCC – James), Columbus, OH, USA.

³⁰⁷The University of Texas School of Biomedical Informatics (SBMI) at Houston, Houston, TX, USA.

³⁰⁸Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

³⁰⁹Physics Division, Optimization and Systems Biology Lab, Massachusetts General Hospital, Boston, MA, USA.

³¹⁰Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

³¹¹Bioinformatics Group, Department of Computer Science, University of Leipzig, Leipzig, Germany.

³¹²Interdisciplinary Center for Bioinformatics, University of Leipzig, Leipzig, Germany.

³¹³Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

³¹⁴Computational Biology, Leibniz Institute on Aging - Fritz Lipmann Institute (FLI), Jena, Germany.

³¹⁵Transcriptome Bioinformatics, LIFE Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany.

³¹⁶Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA.

³¹⁷Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

³¹⁸Research Center for Advanced Science and Technology, The University of Tokyo, Minato-ku, Tokyo, Japan.

³¹⁹Van Andel Research Institute, Grand Rapids, MI, USA.

³²⁰Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

³²¹Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

³²²The Hebrew University Faculty of Medicine, Jerusalem, Israel.

³²³German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

³²⁴Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

³²⁵McKusick-Nathans Institute of Genetic Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

³²⁶Foundation Medicine, Cambridge, MA, USA.

³²⁷Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

³²⁸Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.

³²⁹University of Cambridge, Cambridge, UK.

³³⁰Brandeis University, Waltham, MA, USA.

³³¹Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.

³³²Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.

³³³A. A. Kharkevich Institute of Information Transmission Problems, Moscow, Russia.

³³⁴Oncology and Immunology, Dmitry Rogachev National Research Center of Pediatric Hematology, Moscow, Russia.

³³⁵Skolkovo Institute of Science and Technology, Moscow, Russia.

³³⁶Center for Medical Innovation, Seoul National University Hospital, Seoul, South Korea.

³³⁷Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.

³³⁸Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

³³⁹School of Medicine/School of Mathematics and Statistics, University of St Andrews, St Andrews, UK.

³⁴⁰Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

³⁴¹Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.

³⁴²Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.

³⁴³Ben May Department for Cancer Research, Department of Human Genetics, The University of Chicago, Chicago, IL, USA.

³⁴⁴Tri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY, USA.

³⁴⁵Department of Bioengineering, and Department of Cellular and Molecular Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.

³⁴⁶Centre for Computational Biology, Duke-NUS Medical School, Singapore, Singapore.

³⁴⁷Department of Computer Science, University of Helsinki, Helsinki, Finland.

³⁴⁸Institute of Biotechnology, University of Helsinki, Helsinki, Finland.

³⁴⁹Organismal and Evolutionary Biology Research Programme, University of Helsinki, Helsinki, Finland.

³⁵⁰Programme in Cancer & Stem Cell Biology, Centre for Computational Biology, Duke-NUS Medical School, Singapore, Singapore.

³⁵¹Academic Department of Medical Genetics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

³⁵²MRC Cancer Unit, University of Cambridge, Cambridge, UK.

³⁵³The University of Cambridge School of Clinical Medicine, Cambridge, UK.

³⁵⁴Department of Applied Mathematics and Theoretical Physics, Centre for Mathematical Sciences, University of Cambridge, Cambridge, UK.

³⁵⁵Department of Statistics, Columbia University, New York, NY, USA.

³⁵⁶Duke-NUS Medical School, Singapore, Singapore.

³⁵⁷School of Electronic Information and Communications, Huazhong University of Science and Technology, Wuhan, China.

³⁵⁸The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, University of New South Wales, Sydney, New South Wales, Australia.

³⁵⁹MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, UK.

³⁶⁰Bioinformatics Group, Division of Molecular Biology, Department of Biology, Faculty of Science, University of Zagreb, Zagreb, Croatia.

³⁶¹Department of Bioinformatics, Division of Cancer Genomics, National Cancer Center Research Institute, National Cancer Center, Tokyo, Japan.

³⁶²University of Glasgow, Glasgow, UK.

³⁶³MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.

³⁶⁴Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, UK.

³⁶⁵School of Computing Science, University of Glasgow, Glasgow, UK.

³⁶⁶South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Liverpool, New South Wales, Australia.

³⁶⁷West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.

³⁶⁸University of Melbourne Centre for Cancer Research, Melbourne, Victoria, Australia.

³⁶⁹Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.

³⁷⁰Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.

³⁷¹The Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.

³⁷²Walter + Eliza Hall Institute, Parkville, Victoria, Australia.

³⁷³University of Cologne, Cologne, Germany.

³⁷⁴The Edward S. Rogers Sr Department of Electrical and Computer Engineering, University of Toronto, Toronto, Ontario, Canada.

³⁷⁵University of Ljubljana, Ljubljana, Slovenia.

³⁷⁶Department of Public Health Sciences, The University of Chicago, Chicago, IL, USA.

³⁷⁷Research Institute, NorthShore University HealthSystem, Evanston, IL, USA.

³⁷⁸Department of Statistics, University of California Santa Cruz, Santa Cruz, CA, USA.

³⁷⁹Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

³⁸⁰University of Toronto, Toronto, Ontario, Canada.

³⁸¹Department of Computer Science, Carleton College, Northfield, MN, USA.

³⁸²Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.

³⁸³Center for Psychiatric Genetics, NorthShore University HealthSystem, Evanston, IL, USA.

³⁸⁴Argmix Consulting, North Vancouver, British Columbia, Canada.

³⁸⁵Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

³⁸⁶Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

³⁸⁷The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

³⁸⁸Molecular and Medical Genetics, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

³⁸⁹Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.

³⁹⁰Baylor College of Medicine, Houston, TX, USA.

³⁹¹Department of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, MD, USA.

³⁹²Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany.

³⁹³University Medical Center Hamburg-Eppendorf, Bioinformatics Core, Hamburg, Germany.

³⁹⁴Earlham Institute, Norwich, UK.

³⁹⁵Norwich Medical School, University of East Anglia, Norwich, UK.

³⁹⁶The Institute of Cancer Research, London, UK.

³⁹⁷University of East Anglia, Norwich, UK.

³⁹⁸German Center for Infection Research (DZIF), Partner Site Hamburg-Borstel-Lübeck-Riems, Hamburg, Germany.

³⁹⁹Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

⁴⁰⁰Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

⁴⁰¹Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.

⁴⁰²QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

⁴⁰³Victorian Institute of Forensic Medicine, Southbank, Victoria, Australia.

⁴⁰⁴University of Pennsylvania, Philadelphia, PA, USA.

⁴⁰⁵Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.

⁴⁰⁶Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.

⁴⁰⁷Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia.

⁴⁰⁸Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.

⁴⁰⁹Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.

⁴¹⁰Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.

⁴¹¹Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria, Australia.

⁴¹²Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.

⁴¹³Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia. .

⁴¹⁴Westmead Clinical School, The Westmead Institute for Medical Research, New South Wales, Australia.

⁴¹⁵Department of Surgery, Pancreas Institute, University and Hospital Trust of Verona, Verona, Italy.

⁴¹⁶Department of Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

⁴¹⁷Surgical Oncology Group, Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia.

⁴¹⁸Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.

⁴¹⁹ARC-Net Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, Italy.

⁴²⁰Illawarra Shoalhaven Local Health District L³ Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, New South Wales, Australia.

⁴²¹Department of Pathology, University of Sydney, Sydney, New South Wales, Australia.

⁴²²School of Biological Sciences, The University of Auckland, Auckland, New Zealand.

⁴²³Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy.

⁴²⁴Department of Medicine, Section of Endocrinology, University and Hospital Trust of Verona, Verona, Italy.

⁴²⁵Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK.

⁴²⁶Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.

⁴²⁷Academic Unit of Surgery, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.

⁴²⁸Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

⁴²⁹Discipline of Surgery, Western Sydney University, Penrith, New South Wales, Australia.

⁴³⁰Institute of Cancer Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

⁴³¹The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, University of New South Wales, Sydney, New South Wales, Australia.

⁴³²School of Environmental and Life Sciences, Faculty of Science, The University of Newcastle, Ourimbah, New South Wales, Australia.

⁴³³Eastern Clinical School, Monash University, Melbourne, Victoria, Australia.

⁴³⁴Epworth HealthCare, Richmond, Victoria, Australia.

⁴³⁵Olivia Newton-John Cancer Research Institute, La Trobe University, Heidelberg, Victoria, Australia.

⁴³⁶Melanoma Institute Australia, The University of Sydney, Wollstonecraft, New South Wales, Australia.

⁴³⁷Children's Hospital at Westmead, The University of Sydney, Sydney, New South Wales, Australia.

⁴³⁸Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.

⁴³⁹Australian Institute of Tropical Health and Medicine, James Cook University, Douglas, Queensland, Australia.

⁴⁴⁰Bioplatforms Australia, North Ryde, New South Wales, Australia.

⁴⁴¹Melanoma Institute Australia, Macquarie University, Wollstonecraft, New South Wales, Australia.

⁴⁴²Children's Medical Research Institute, Sydney, New South Wales, Australia.

⁴⁴³Melanoma Institute Australia, The University of Sydney, Wollstonecraft, New South Wales, Australia.

⁴⁴⁴Centre for Cancer Research, The Westmead Millennium Institute for Medical Research, University of Sydney, Westmead Hospital, Sydney, New South Wales, Australia.

⁴⁴⁵Translational Cancer Research Centre, The University of Sydney at the Westmead Institute, Sydney, New South Wales, Australia.

⁴⁴⁶Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

⁴⁴⁷School of Mathematics and Statistics, The University of Sydney, Sydney, New South Wales, Australia.

⁴⁴⁸Melanoma Institute Australia, The University of Sydney, Wollstonecraft, New South Wales, Australia.

⁴⁴⁹The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.

⁴⁵⁰Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

⁴⁵¹Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

⁴⁵²Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

⁴⁵³PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

⁴⁵⁴BioSpecimen Sciences Program, University Health Network, Toronto, Ontario, Canada.

⁴⁵⁵Hepatobiliary/Pancreatic Surgical Oncology Program, University Health Network, Toronto, Ontario, Canada.

⁴⁵⁶Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.

⁴⁵⁷Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

⁴⁵⁸University of Nebraska Medical Center, Omaha, NE, USA.

⁴⁵⁹BioSpecimen Sciences Program, University Health Network, Toronto, Ontario, Canada.

⁴⁶⁰Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

⁴⁶¹University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

⁴⁶²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

⁴⁶³BioSpecimen Sciences, Laboratory Medicine (Toronto), Medical Biophysics, PanCuRX, Toronto, Ontario, Canada.

⁴⁶⁴Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

⁴⁶⁵Department of Pathology, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

⁴⁶⁶Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

⁴⁶⁷Department of Biochemistry and Molecular Medicine, University California at Davis, Sacramento, CA, USA.

⁴⁶⁸Human Longevity, San Diego, CA, USA.

⁴⁶⁹Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

⁴⁷⁰Genome Informatics Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

⁴⁷¹STTARR Innovation Facility, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

⁴⁷²Department of Pathology, Toronto General Hospital, Toronto, Ontario, Canada.

⁴⁷³CRUK Manchester Institute and Centre, Manchester, UK.

⁴⁷⁴Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.

⁴⁷⁵Manchester Cancer Research Centre, Cancer Division, FBMH, University of Manchester, Manchester, UK.

⁴⁷⁶Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

⁴⁷⁷Hefei University of Technology, Anhui, China.

⁴⁷⁸State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Shaanxi, China.

⁴⁷⁹Fourth Military Medical University, Shaanxi, China.

⁴⁸⁰Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.

⁴⁸¹Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

⁴⁸²Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Leeds, UK.

⁴⁸³Canadian Center for Computational Genomics, McGill University, Montreal, Quebec, Canada.

⁴⁸⁴Department of Human Genetics, McGill University, Montreal, Quebec, Canada.

⁴⁸⁵International Agency for Research on Cancer, Lyon, France.

⁴⁸⁶McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.

⁴⁸⁷St. James Institute of Oncology, University of Leeds, St James's University Hospital, Leeds, UK.

⁴⁸⁸Institute of Mathematics and Computer Science, University of Latvia, Riga, Latvia.

⁴⁸⁹Centre National de Génotypage, CEA - Institute de Génomique, Evry, France.

⁴⁹⁰Department of Oncology, Gil Medical Center, Gachon University, Incheon, South Korea.

⁴⁹¹Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.

⁴⁹²Los Alamos National Laboratory, Los Alamos, NM, USA.

⁴⁹³Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.

⁴⁹⁴Lund University, Lund, Sweden.

⁴⁹⁵Translational Research Lab, Centre Léon Bérard, Lyon, France.

⁴⁹⁶Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, The Netherlands.

⁴⁹⁷Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

⁴⁹⁸Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

⁴⁹⁹Li Ka Shing Centre, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.

⁵⁰⁰Department of Oncology, University of Cambridge, Cambridge, UK.

⁵⁰¹Breast Cancer Translational Research Laboratory J. C. Heuson, Institut Jules Bordet, Brussels, Belgium.

⁵⁰²Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

⁵⁰³Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Center for Oncological Research, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

⁵⁰⁴Department of Gynecology & Obstetrics and Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.

⁵⁰⁵Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavík, Iceland.

⁵⁰⁶Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, The Netherlands.

⁵⁰⁷National Genotyping Center, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.

⁵⁰⁸Department of Pathology, Oslo University Hospital Ullevål, Oslo, Norway.

⁵⁰⁹Faculty of Medicine and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

⁵¹⁰Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

⁵¹¹Department of Pathology, Skåne University Hospital, Lund University, Lund, Sweden.

⁵¹²Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands.

⁵¹³Department of Pathology, College of Medicine, Hanyang University, Seoul, South Korea.

⁵¹⁴Department of Pathology, Asan Medical Center, College of Medicine, Ulsan University, Songpa-gu, Seoul, South Korea.

⁵¹⁵The Netherlands Cancer Institute, Amsterdam, The Netherlands.

⁵¹⁶Department of Surgery, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA.

⁵¹⁷Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

⁵¹⁸Department of Clinical Science, University of Bergen, Bergen, Norway.

⁵¹⁹Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

⁵²⁰The University of Queensland Centre for Clinical Research, The Royal Brisbane & Women's Hospital, Herston, Queensland, Australia.

⁵²¹Department of Pathology, Institut Jules Bordet, Brussels, Belgium.

⁵²²Institute for Bioengineering and Biopharmaceutical Research (IBBR), Hanyang University, Seoul, South Korea.

⁵²³University of Oslo, Oslo, Norway.

⁵²⁴Institut Bergonié, Bordeaux, France.

⁵²⁵Department of Research Oncology, Guy's Hospital, King's Health Partners AHSC, King's College London School of Medicine, London, UK.

⁵²⁶University Hospital of Minjoz, INSERM UMR 1098, Besançon, France.

⁵²⁷Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.

⁵²⁸East of Scotland Breast Service, Ninewells Hospital, Aberdeen, UK.

⁵²⁹Oncologie Sénologie, ICM Institut Régional du Cancer, Montpellier, France.

⁵³⁰Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

⁵³¹University of Iceland, Reykjavik, Iceland.

⁵³²Dundee Cancer Centre, Ninewells Hospital, Dundee, UK.

⁵³³Institut Curie, INSERM Unit 830, Paris, France.

⁵³⁴Department of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

⁵³⁵Department of General Surgery, Singapore General Hospital, Singapore, Singapore.

⁵³⁶INCa-Synergie, Centre Léon Bérard, Université Lyon, Lyon, France.

⁵³⁷Giovanni Paolo II/I.R.C.C.S. Cancer Institute, Bari, Italy.

⁵³⁸Department of Biopathology, Centre Léon Bérard, Lyon, France.

⁵³⁹Université Claude Bernard Lyon 1, Villeurbanne, France.

⁵⁴⁰NCCS-VARI Translational Research Laboratory, National Cancer Centre Singapore, Singapore, Singapore.

⁵⁴¹Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.

⁵⁴²Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

⁵⁴³Institute of Human Genetics, Christian-Albrechts-University, Kiel, Germany.

⁵⁴⁴Institute of Human Genetics, University of Ulm, Ulm, Germany.

⁵⁴⁵Hematopathology Section, Institute of Pathology, Christian-Albrechts-University, Kiel, Germany.

⁵⁴⁶University Hospital of Ulm, Ulm, Germany.

⁵⁴⁷Department of Human Genetics, Hannover Medical School, Hannover, Germany.

⁵⁴⁸Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.

⁵⁴⁹Department of Internal Medicine/Hematology, Friedrich-Ebert-Hospital, Neumünster, Germany.

⁵⁵⁰Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

⁵⁵¹Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany.

⁵⁵²Department of Medicine II, University of Würzburg, Würzburg, Germany.

⁵⁵³Senckenberg Institute of Pathology, University of Frankfurt Medical School, Frankfurt, Germany.

⁵⁵⁴Institute of Pathology, Charité–University Medicine Berlin, Berlin, Germany.

⁵⁵⁵Department for Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany.

⁵⁵⁶Institute for Medical Informatics Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.

⁵⁵⁷Department of Hematology and Oncology, Georg-Augusts-University of Göttingen, Göttingen, Germany.

⁵⁵⁸Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.

⁵⁵⁹MVZ Department of Oncology, PraxisClinic am Johannisplatz, Leipzig, Germany.

⁵⁶⁰Institute of Pathology, Ulm University and University Hospital of Ulm, Ulm, Germany.

⁵⁶¹Department of Pathology, Robert-Bosch-Hospital, Stuttgart, Germany.

⁵⁶² Pediatric Hematology and Oncology, University Hospital Giessen, Giessen, Germany.

⁵⁶³Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany.

⁵⁶⁴Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany.

⁵⁶⁵Department of General Internal Medicine, University Kiel, Kiel, Germany.

⁵⁶⁶Clinic for Hematology and Oncology, St-Antonius-Hospital, Eschweiler, Germany.

⁵⁶⁷Department for Internal Medicine III, University of Ulm and University Hospital of Ulm, Ulm, Germany.

⁵⁶⁸Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

⁵⁶⁹Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany.

⁵⁷⁰University of Düsseldorf, Düsseldorf, Germany.

⁵⁷¹Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Max Planck Institute for Molecular Genetics, Berlin, Germany.

⁵⁷²St Jude Children's Research Hospital, Memphis, TN, USA.

⁵⁷³Heidelberg University Hospital, Heidelberg, Germany.

⁵⁷⁴Genomics and Proteomics Core Facility High Throughput Sequencing Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.

⁵⁷⁵Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany.

⁵⁷⁶University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

⁵⁷⁷Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

⁵⁷⁸Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

⁵⁷⁹Division of Cancer Genome Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.

⁵⁸⁰National Institute of Biomedical Genomics, Kalyani, India.

⁵⁸¹Advanced Centre for Treatment Research & Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.

⁵⁸²Department of Pathology, General Hospital of Treviso, Department of Medicine, University of Padua, Treviso, Italy.

⁵⁸³Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy.

⁵⁸⁴Department of Hepatobiliary and Pancreatic Oncology, Hepatobiliary and Pancreatic Surgery Division, Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.

⁵⁸⁵Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

⁵⁸⁶Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.

⁵⁸⁷Department of Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

⁵⁸⁸Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

⁵⁸⁹Gastric Surgery Division, Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.

⁵⁹⁰Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

⁵⁹¹Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, University of Tokyo, Tokyo, Japan.

⁵⁹²Department of Cancer Genome Informatics, Graduate School of Medicine, Osaka University, Osaka, Japan.

⁵⁹³Hiroshima University, Hiroshima, Japan.

⁵⁹⁴Tokyo Women's Medical University, Tokyo, Japan.

⁵⁹⁵Osaka International Cancer Center, Osaka, Japan.

⁵⁹⁶Wakayama Medical University, Wakayama, Japan.

⁵⁹⁷Hokkaido University, Sapporo, Japan.

⁵⁹⁸Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.

⁵⁹⁹Cholangiocarcinoma Screening and Care Program and Liver Fluke and Cholangiocarcinoma Research Centre, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

⁶⁰⁰Lymphoma Genomic Translational Research Laboratory, National Cancer Centre, Singapore, Singapore.

⁶⁰¹Center of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania.

⁶⁰²Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, School of Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea.

⁶⁰³Pathology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

⁶⁰⁴Hematology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

⁶⁰⁵Department of Biochemistry and Molecular Biology, Faculty of Medicine, University Institute of Oncology-IUOPA, Oviedo, Spain.

⁶⁰⁶Anatomia Patológica, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

⁶⁰⁷Spanish Ministry of Science and Innovation, Madrid, Spain.

⁶⁰⁸Royal National Orthopaedic Hospital (Bolsover), London, UK.

⁶⁰⁹Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.

⁶¹⁰Institute of Clinical Medicine and Institute of Oral Biology, University of Oslo, Oslo, Norway.

⁶¹¹Research Department of Pathology, University College London Cancer Institute, London, UK.

⁶¹²East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

⁶¹³Royal National Orthopaedic Hospital (Stanmore), London, UK.

⁶¹⁴Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.

⁶¹⁵Department of Pathology (Research), University College London Cancer Institute, London, UK.

⁶¹⁶Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

⁶¹⁷University of Pavia, Pavia, Italy.

⁶¹⁸Karolinska Institute, Stockholm, Sweden.

⁶¹⁹Wellcome Sanger Institute, Cambridge, UK.

⁶²⁰University of Oxford, Oxford, UK.

⁶²¹Salford Royal NHS Foundation Trust, Salford, UK.

⁶²²Gloucester Royal Hospital, Gloucester, UK.

⁶²³Royal Stoke University Hospital, Stoke-on-Trent, UK.

⁶²⁴St Thomas's Hospital, London, UK.

⁶²⁵Imperial College NHS Trust, Imperial College London, London, UK.

⁶²⁶Department of Histopathology, Salford Royal NHS Foundation Trust, Salford, UK.

⁶²⁷Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

⁶²⁸Edinburgh Royal Infirmary, Edinburgh, UK.

⁶²⁹Barking Havering and Redbridge University Hospitals NHS Trust, Romford, UK.

⁶³⁰King's College London and Guy's and St Thomas' NHS Foundation Trust, London UK.

⁶³¹Cambridge Oesophagogastric Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

⁶³²Nottingham University Hospitals NHS Trust, Nottingham, UK.

⁶³³St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK.

⁶³⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

⁶³⁵Norfolk and Norwich University Hospital NHS Trust, Norwich, UK.

⁶³⁶University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.

⁶³⁷University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

⁶³⁸Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK.

⁶³⁹School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

⁶⁴⁰Wythenshawe Hospital, Manchester, UK.

⁶⁴¹Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

⁶⁴²Royal Marsden NHS Foundation Trust, London and Sutton, London, UK.

⁶⁴³University Hospital Southampton NHS Foundation Trust, Southampton, UK.

⁶⁴⁴HCA Laboratories, London, UK.

⁶⁴⁵University of Liverpool, Liverpool, UK.

⁶⁴⁶Academic Urology Group, Department of Surgery, University of Cambridge, Cambridge, UK.

⁶⁴⁷University of Oxford, Oxford, Oxford, UK.

⁶⁴⁸Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

⁶⁴⁹Second Military Medical University, Shanghai, China.

⁶⁵⁰Department of Surgery and Cancer, Imperial College London, London, UK.

⁶⁵¹The Chinese University of Hong Kong, Shatin, Hong Kong, China.

⁶⁵²Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Headington, Oxford, UK.

⁶⁵³Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

⁶⁵⁴Department of Bioinformatics and Computational Biology and Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

⁶⁵⁵Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

⁶⁵⁶Canada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, British Columbia, Canada.

⁶⁵⁷Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

⁶⁵⁸University Health Network, Toronto, Ontario, Canada.

⁶⁵⁹Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

⁶⁶⁰Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

⁶⁶¹Research Health Analytics and Informatics, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

⁶⁶²Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.

⁶⁶³Department of Surgery and Department of Oncology, University of Calgary, Calgary, Alberta, Canada.

⁶⁶⁴Buck Institute for Research on Aging, Novato, CA, USA.

⁶⁶⁵Duke University Medical Center, Durham, NC, USA.

⁶⁶⁶USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

⁶⁶⁷The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.

⁶⁶⁸Department of Dermatology and Department of Pathology, Yale University, New Haven, CT, USA.

⁶⁶⁹Fox Chase Cancer Center, Philadelphia, PA, USA.

⁶⁷⁰Department of Surgery, Division of Thoracic Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

⁶⁷¹University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

⁶⁷²University of Alabama at Birmingham, Birmingham, AL, USA.

⁶⁷³Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.

⁶⁷⁴Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA.

⁶⁷⁵Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.

⁶⁷⁶International Genomics Consortium, Phoenix, AZ, USA.

⁶⁷⁷Department of Pediatrics and Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

⁶⁷⁸Department of Pathology, UPMC Shadyside, Pittsburgh, PA, USA.

⁶⁷⁹Center for Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

⁶⁸⁰Department of Neuro-Oncology, Istituto Neurologico Besta, Milan, Italy.

⁶⁸¹University of Queensland Thoracic Research Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.

⁶⁸²Department of Neurosurgery, University of Florida, Gainesville, FL, USA.

⁶⁸³Center for Biomedical Informatics, Harvard Medical School, Boston, MA, USA.

⁶⁸⁴Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

⁶⁸⁵Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

⁶⁸⁶Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

⁶⁸⁷Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.

⁶⁸⁸Department of Internal Medicine, Division of Medical Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

⁶⁸⁹University of Tennessee Health Science Center for Cancer Research, Memphis, TN, USA.

⁶⁹⁰Centre for Translational and Applied Genomics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

⁶⁹¹Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA.

⁶⁹²Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.

⁶⁹³Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

⁶⁹⁴Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.

⁶⁹⁵Indivumed, Hamburg, Germany.

⁶⁹⁶Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, School of Medicine, Keimyung University Dong-san Medical Center, Daegu, South Korea.

⁶⁹⁷Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

⁶⁹⁸Department of Surgery, School of Medicine and Health Science, The George Washington University, Washington, DC, USA.

⁶⁹⁹Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

⁷⁰⁰National Cancer Center, Gyeonggi, South Korea.

⁷⁰¹ILSbio, LLC Biobank, Chestertown, MD, USA.

⁷⁰²Gynecologic Oncology, NYU Laura and Isaac Perlmutter Cancer Center, New York University, New York, NY, USA.

⁷⁰³Division of Oncology, Stem Cell Biology Section, Washington University School of Medicine, St. Louis, MO, USA.

⁷⁰⁴Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

⁷⁰⁵Institute for Systems Biology, Seattle, WA, USA.

⁷⁰⁶Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.

⁷⁰⁷Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.

⁷⁰⁸Department of Surgery, Duke University, Durham, NC, USA.

⁷⁰⁹Department of Obstetrics, Gynecology and Reproductive Services, University of California San Francisco, San Francisco, CA, USA.

⁷¹⁰Department of Neurology and Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA.

⁷¹¹Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

⁷¹²Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA.

⁷¹³Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA.

⁷¹⁴Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

⁷¹⁵Penrose St Francis Health Services, Colorado Springs, CO, USA.

⁷¹⁶The University of Chicago, Chicago, IL, USA.

⁷¹⁷Department of Neurology, Mayo Clinic, Rochester, MN, USA.

⁷¹⁸Center for Liver Cancer, Research Institute and Hospital, National Cancer Center, Gyeonggi, South Korea.

⁷¹⁹Department of Genetics and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

⁷²⁰NYU Langone Medical Center, New York, NY, USA.

⁷²¹Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.

⁷²²Department of Genetics, Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

⁷²³Helen F. Graham Cancer Center at Christiana Care Health Systems, Newark, DE, USA.

⁷²⁴Cureline, South San Francisco, CA, USA.

⁷²⁵Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA.

⁷²⁶Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

⁷²⁷Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.

⁷²⁸Ohio State University College of Medicine and Arthur G. James Comprehensive Cancer Center, Columbus, OH, USA.

⁷²⁹Research Computing Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

⁷³⁰Analytical Biological Services, Wilmington, DE, USA.

⁷³¹Department of Dermatology, University Hospital Essen, Westdeutsches Tumorzentrum and German Cancer Consortium, Essen, Germany.

⁷³²University of Pittsburgh, Pittsburgh, PA, USA.

⁷³³Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, USA.

⁷³⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

⁷³⁵Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

⁷³⁶Department of Gynecologic Oncology and Reproductive Medicine, and Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

⁷³⁷Department of Urology, Mayo Clinic, Rochester, MN, USA.

⁷³⁸Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

⁷³⁹Department of Neurosurgery, Department of Hematology and Department of Medical Oncology, Winship Cancer Institute and School of Medicine, Emory University, Atlanta, GA, USA.

⁷⁴⁰Georgia Regents University Cancer Center, Augusta, GA, USA.

⁷⁴¹Thoracic Oncology Laboratory, Mayo Clinic, Rochester, MN, USA.

⁷⁴²Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.

⁷⁴³Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA.

⁷⁴⁴International Institute for Molecular Oncology, Poznań, Poland.

⁷⁴⁵Poznan University of Medical Sciences, Poznań, Poland.

⁷⁴⁶Edison Family Center for Genome Sciences and Systems Biology, Washington University, St Louis, MO, USA.

⁷⁴⁷These authors jointly coordinated the PCAWG Consortium: Peter J. Campbell, Gad Getz, Joshua M. Stuart Lincoln D. Stein & Jan O. Korbel